SANUWAVE Health, Inc. Form DEF 14C April 16, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 14C INFORMATION

Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934

Check the appropriate box:

- [] Preliminary Information Statement
- [] Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d) (2))
- [X] Definitive Information Statement

SANUWAVE HEALTH, INC.

(Name of Registrant as Specified in Its Charter)

Payment of Filing Fee (check the appropriate box):

- [X] No fee required
- [] Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

(1)	Title of each class of securities to which transaction applies:

- (2) Aggregate number of securities to which transaction applies:
- (3)Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

(4)		Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:

[] Fee paid previously with preliminary materials.

[] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a) (2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

(1)	Amount Previously Paid:
(2)	Form, Schedule or Registration Statement No.:

Edgar Filing: SANUWAVE Health, Inc. - Form DEF 14C

Filing Party:	(3)
Date Filed:	(4)

SANUWAVE HEALTH, INC. 11680 Great Oaks Way, Suite 350 Alpharetta, Georgia 30022

NOTICE OF STOCKHOLDER ACTION TAKEN BY WRITTEN CONSENT

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY

Dear Stockholders:

This information statement ("Information Statement") is being furnished to holders of record of the common stock, par value \$0.001 per share (the "Common Stock") of SANUWAVE Health, Inc., a Nevada corporation (the "Company"), at the close of business on April 3, 2012 with respect to certain corporate actions of the Company. This Information Statement is first being mailed or furnished to the stockholders of the Company on or about April 16, 2012.

The purpose of this Information Statement is to notify stockholders of the Company that, on April 3, 2012, the Company received a written consent in lieu of a meeting of stockholders from the holders of 10,522,493 shares of Common Stock (representing 50.3% of the issued and outstanding shares of Common Stock of the Company on April 3, 2012). The written consent adopted resolutions approving amendments to the Company's articles of incorporation to (i) increase the number of shares of authorized stock of the Company from 55,000,000 shares to 155,000,000 shares, and (ii) vest authority in the board of directors to prescribe the classes, series and number of shares of each class or series of stock and the voting powers, designations, preferences, limitations, restrictions and relative rights of each class or series of stock.

ONLY THE STOCKHOLDERS OF RECORD AT THE CLOSE OF BUSINESS ON APRIL 3, 2012 ARE ENTITLED TO NOTICE OF THE CORPORATE ACTION. STOCKHOLDERS WHO HOLD IN EXCESS OF 50% OF THE COMPANY'S SHARES OF VOTING CAPITAL STOCK ENTITLED TO VOTE ON THE ACTION HAVE VOTED IN FAVOR OF THE ACTION. AS A RESULT, THE ACTION HAS BEEN APPROVED WITHOUT THE AFFIRMATIVE VOTE OF ANY OTHER STOCKHOLDERS OF THE COMPANY. THIS ACTION IS EXPECTED TO BE EFFECTIVE ON A DATE THAT IS AT LEAST 20 DAYS AFTER THE MAILING OF THIS INFORMATION STATEMENT.

The Company's board of directors is not soliciting your proxy. This Information Statement is being furnished to you solely for the purpose of informing stockholders of the matters described herein in compliance with Section 14 Securities Exchange Act of 1934, as amended. The Company has asked brokers and other custodians, nominees and fiduciaries to forward this Information Statement to the beneficial owners of the Common Stock held of record by such persons and will reimburse such persons for out-of-pocket expenses incurred in forwarding such material.

BY ORDER OF THE BOARD OF DIRECTORS

/s/ Christopher M. Cashman Christopher M. Cashman President and Chief Executive Officer

April 16, 2012

Edgar Filing: SANUWAVE Health, Inc. - Form DEF 14C

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF THE INFORMATION STATEMENT

This Information Statement is available on the Internet at www.sanuwave.com/investors/SEC.

SANUWAVE HEALTH, INC. 11680 Great Oaks Way, Suite 350 Alpharetta, Georgia 30022

INFORMATION STATEMENT PURSUANT TO SECTION 14 OF THE SECURITIES AND EXCHANGE ACT OF 1934 AND REGULATION 14C AND SCHEDULE 14C THEREUNDER

WE ARE NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

This information statement ("Information Statement") is being furnished to holders of record of the common stock, par value \$0.001 per share (the "Common Stock"), at the close of business on April 3, 2012 (the "Record Date") of SANUWAVE Health, Inc., a Nevada corporation (the "Company"), with respect to certain corporate actions of the Company. This Information Statement is first being mailed or furnished to the stockholders of the Company who are entitled to such materials on or about April 16, 2012.

This Information Statement is being circulated to advise the stockholders of action taken without a meeting upon the written consent of the holders of a majority of the outstanding shares of the Common Stock of the Company.

ABOUT THIS INFORMATION STATEMENT

What is the purpose of this Information Statement?

This Information Statement is being provided pursuant to Section 14 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to notify stockholders of the Company, as of the close of business on the Record Date, of the corporate actions taken pursuant to the written consent of two stockholders holding, in the aggregate, a majority of the voting power of the Company. The majority of stockholders of the Company's Common Stock have approved amendments to the Company's Articles of Incorporation to (i) increase the number of shares of authorized stock of the Company from 55,000,000 shares to 155,000,000 shares, and (ii) vest authority in the board of directors (the "Board") to prescribe the classes, series and number of shares of each class or series of stock and the voting powers, designations, preferences, limitations, restrictions and relative rights of each class or series of stock (the "Action"). In order to eliminate the costs and management time involved in holding a special meeting, and in order to effect the corporate action as soon as possible, the Company decided to proceed with the corporate action by obtaining the written consent of stockholders holding a majority of the voting power of the Company.

Who is entitled to notice?

All holders of shares of Common Stock of record on the close of business on the Record Date are entitled to notice of the Action.

On what corporate matters did the majority stockholders vote?

Two stockholders who hold, in the aggregate, approximately 50.3% of the total issued and outstanding voting capital stock of the Company on the Record Date, representing a majority of the issued and outstanding voting capital stock entitled to vote on the Action. The stockholders have voted for and, thereby, approved, the following:

- For approval of an amendment to the Articles of Incorporation of the Company to increase the number of shares of authorized stock of the Company from 55,000,000 shares to 155,000,000 shares.
- For approval of an amendment to the Articles of Incorporation of the Company to vest authority in the board of directors to prescribe the classes, series and number of shares of each class or series of stock and the voting powers, designations, preferences, limitations, restrictions and relative rights of each class or series of stock

How many shares of voting stock were outstanding on April 3, 2012 (the Record Date)?

On the Record Date, there were 20,907,536 shares of the Company's Common Stock issued and outstanding.

What vote is required to approve the Action described in this Information Statement?

In order to amend the Articles of Incorporation of the Company to effect the Action, the affirmative vote of a majority of the voting capital stock was required. On April 3, 2012, two stockholders of the Company who own a majority of the outstanding shares voted in favor of the Action. Under Section 78.320 of the Nevada Revised Statutes, certain activities requiring stockholder approval (including the Action) may be taken by obtaining the written consent and approval of more than 50% of the holders of voting stock entitled to vote on such action in lieu of a meeting of the stockholders. Because the two stockholders held 10,522,493 shares of Common Stock entitled to vote on the Action on the Record Date (which shares are equal to approximately 50.3% of the total issued and outstanding voting capital stock of the Company on the Record Date), no meeting of or further action by the stockholders in connection with the Action is required.

The two stockholders who voted to approve the Action are:

	Number of		
	Shares of	Percent of	
	Common	Shares	
Name of Stockholder	Stock Owned	Outstanding	
Prides Capital Fund I, LP	9,081,989	43.4	%
Kevin and Margaret Richardson	1,440,504	6.9	%

Who is paying the cost of this information statement?

The Company will pay for preparing, printing and mailing this Information Statement.

ACTION

Amendment to the Company's Articles of Incorporation to Increase the Number of Authorized Shares of Stock

On March 23, 2012, the Board adopted a resolution declaring it advisable to amend the Company's Articles of Incorporation to increase the number of shares of authorized stock of the Company from 55,000,000 shares to 155,000,000 shares. On April 3, 2012, the Company received a written consent in lieu of a meeting of stockholders from the holders of 10,522,493 shares of Common Stock (representing approximately 50.3% of the issued and outstanding shares of Common Stock on the Record Date) approving this amendment (as part of the Action described in this Information Statement). A copy of the Certificate of Amendment to the Articles of Incorporation is attached as Exhibit A hereto.

Purpose of Increasing the Number of Authorized Shares of Stock of the Company

The continuation of the Company's business is dependent upon raising additional capital, which may include the issuance of common or preferred stock, securities convertible into Common Stock, or secured or unsecured debt, an investment by a strategic partner in a specific clinical indication or market opportunity, selling all or a portion of the Company's assets, liquidating assets, or seeking relief through a filing under the U.S. Bankruptcy Code. The Company has formed a special committee of the Board who has retained the services of Canaccord Genuity Inc., a leading investment bank, to explore capital fund raising and/or strategic options for the Company. To the extent these options will require the Company to issue additional equity securities, the Company needs to increase the number of authorized shares.

Effects of the Increase in Authorized Stock

The additional shares of capital stock will have the same rights as the presently authorized shares, including the right to cast one vote per share of stock. Although the authorization of additional shares will not, in itself, have any effect on the rights of any holder of our Common Stock, the future issuance of additional shares of Common Stock (other than by way of a stock split or dividend) would have the effect of diluting the voting rights and could have the effect of diluting earnings per share and book value per share of existing shareholders.

It is possible that some of these additional shares could be used in the future for various other purposes without further shareholder approval, except as such approval may be required in particular cases by our charter documents, applicable law or the rules of any stock exchange or other system on which our securities may then be listed. These purposes may include: raising capital, providing equity incentives to employees, officers or directors, establishing strategic relationships with other companies, and expanding the Company's business or product lines through the acquisition of other businesses or products.

The Company could also use the additional shares of capital stock to oppose a hostile takeover attempt or to delay or prevent changes in control or management of the Company. Although the Board's recommendation of the amendment to the Articles of Incorporation was not prompted by the threat of any hostile takeover attempt (nor is the Board currently aware of any such attempts directed at the Company), nevertheless, shareholders should be aware that the amendment could facilitate future efforts by the Company to deter or prevent changes in control of the Company; including transactions in which shareholders of the Company might otherwise receive a premium for their shares over then current market prices.

Amendment to the Company's Articles of Incorporation to Vest Designation Authority in the Board of Directors

On March 23, 2012, the Board adopted a resolution declaring it advisable to amend the Company's Articles of Incorporation to provide that the Board is vested with the authority to prescribe the classes, series and number of shares of each class or series of stock and the voting powers, designations, preferences, limitations, restrictions and relative rights of each class or series of stock. On April 3, 2012, the Company received a written consent in lieu of a meeting of stockholders from the holders of 10,522,493 shares of Common Stock (representing approximately 50.3% of the issued and outstanding shares of Common Stock on the Record Date) approving this amendment (as part of the Action described in this Information Statement). A copy of the Certificate of Amendment to the Articles of Incorporation is attached as Exhibit A hereto.

Purpose of Vesting Designation Authority in the Board

Under Nevada law, corporations may provide for the prescription of classes or series of capital stock, and the number and characteristics of each class or series of capital stock in their articles of incorporation, or, alternatively, may vest such authority in the board of directors of the corporation. In order to maintain flexibility and agility in responding to future financing needs of the Company, the Board believes that it is in the best interests of the Company and its shareholders to vest authority in the Board to make any such future designations without the need for further shareholder action to amend the Articles of Incorporation.

Effects of Vesting Designation Authority in the Board

Vesting designation authority as to future classes or series of the Company's capital stock in the Board will have no direct effect on existing holders of the Company's Common Stock. Any changes in the voting powers, designations, preferences, limitations, restrictions and relative rights of each outstanding class or series of capital stock of the Company may not be changed, unless by affirmative vote of the required number of shareholders prescribed under Nevada law, and may not be changed by action of the Board, irrespective of whether this proposed amendment is made to the Company's Articles of Incorporation.

Holders of the Company's Common Stock would only be affected by this proposed amendment, in so far as further classes or series of capital stock of the Company may be designated by the Board—without the need for shareholder action—with certain rights or privileges (such as, for example, the right to receive dividends) that are superior in certain aspects to the existing Common Stock of the Company. The Board currently has no current plans to issue securities under any such class or series of capital stock.

Effective Date of the Amendments

The increase in the number of authorized shares of the Company to 155,000,000 shares and the vesting of further designation authority in the Board will become effective upon the filing of the Certificate of Amendment to the Company's Articles of Incorporation with Secretary of State of the State of Nevada. Pursuant to Rule 14c-2 under the Exchange Act, the foregoing Action may not become effective until a date that is at least 20 days after the date on which this Information Statement has been mailed to the stockholders of the Company.

Dissenters' Right of Appraisal

Under Nevada law and the Company's Articles of Incorporation and Bylaws, no stockholder has any right to dissent, or is otherwise entitled to appraisal of or payment for their shares of Common Stock as a result of the effectuation of the Action.

No Meeting of Stockholders Required

The Company is not soliciting any votes with regard to the Action. The stockholders that have consented to the Action hold a majority of the total issued and outstanding shares of voting capital stock, sufficient to approve the Action by written consent.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information, as of the Record Date, with respect to the beneficial ownership of the outstanding common stock by (i) any holder of more than five percent (5%), (ii) each of the Company's executive officers, directors and director designees, and (iii) the Company's executive officers, directors and director designees as a group.

	Number of Shares Beneficially	Percent of Shares	
Name of Beneficial Owner (1)	Owned (2)	Outstanding	;
Christopher M. Cashman (3)	2,298,759	10.1	%
Barry J. Jenkins (4)	863,509	4.0	%
Kevin A. Richardson, II (5)	2,892,258	12.9	%
Barbara M. Henagan (6)	30,000	*	
Ronald M. Sparks, Jr. (7)	25,000	*	
Thomas H. Robinson (8)	15,000	*	
John F. Nemelka (9)	11,750	*	
David N. Nemelka (10)	3,080,537	13.7	%
Prides Capital Fund I, LP (11)	10,520,077	47.1	%
NightWatch Capital Partners II, LP (12)	2,108,369	10.0	%
All directors and executive officers as a group (7 persons)	6,136,276	24.6	%

- * Less than 1% of outstanding shares.
- (1) Unless otherwise noted, each beneficial owner has the same address as the Company.
- (2) "Beneficial ownership" includes shares for which an individual, directly or indirectly, has or shares voting or investment power, or both, and also includes options that are exercisable within 60 days of April 3, 2012. Unless otherwise indicated, all of the listed persons have sole voting and investment power over the shares listed opposite their names. Beneficial ownership as reported in the above table has been determined in accordance with Rule 13d-3 of the Exchange Act.
- (3) Includes options to purchase up to 1,860,686 shares of common stock and warrants to purchase up to 8,816 shares of common stock.
- (4) Includes options to purchase up to 657,759 shares of common stock and warrants to purchase up to 3,508 shares of common stock.

(5)

Edgar Filing: SANUWAVE Health, Inc. - Form DEF 14C

Includes options to purchase up to 11,250 shares of common stock and warrants to purchase up to 1,440,504 shares of common stock.

- (6) Includes options to purchase up to 25,000 shares of common stock.
- (7) Includes options to purchase up to 25,000 shares of common stock.
- (8) Includes options to purchase up to 15,000 shares of common stock.
- (9) Includes options to purchase up to 11,250 shares of common stock.
- (10)Based solely on information contained in filings made on schedule 13D, as amended, and on Form 4's with the SEC by the reporting person. Includes warrants to purchase up to1,566,014 shares of common stock. The principal address of David N. Nemelka is 2662 Stonebury Loop Road, Springville, UT 84663.
- (11)Based solely on information contained in filings made on schedule 13D, as amended, with the SEC by the reporting person. Includes warrants to purchase 1,438,088 shares of common stock. The principal business address of Prides Capital Fund, I, LP is 200 State Street, 13th floor, Boston, MA 02109.
- (12)Based solely on information contained in filings made on schedule 13D, as amended, with the SEC by the reporting person. Includes warrants to purchase 204,224 shares of common stock. The principal business address of NightWatch Capital Partners II, LP is 5314 River Run Drive, Suite 350, Provo, UT 84604.

INTEREST OF CERTAIN PERSONS IN OR OPPOSITION TO MATTERS TO BE ACTED UPON

No officer, director or director nominee of the Company has any substantial interest in the matters to be acted upon, other than his role as an officer, director or director nominee of the Company. No director of the Company informed the Company that such director opposed the Action as set forth in this Information Statement.

DELIVERY OF DOCUMENTS TO SECURITY HOLDERS SHARING AN ADDRESS

Only one Information Statement is being delivered to multiple security holders sharing an address unless the Company received contrary instructions from one or more of the security holders. The Company shall deliver promptly, upon written or oral request, a separate copy of the Information Statement to a security holder at a shared address to which a single copy of the document was delivered. A security holder can notify the Company that the security holder wishes to receive a separate copy of the Information Statement by sending a written request to the Company at 11680 Great Oaks Way, Suite 350, Alpharetta, Georgia 30022, or by calling the Company at (770) 419-7525. A security holder may utilize the same address and telephone number to request either separate copies or a single copy for a single address for all future information statements, proxy statements and annual reports.

FORWARD-LOOKING STATEMENTS AND INFORMATION

This Information Statement includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. You can identify our forward-looking statements by the words "expects," "projects," "believes," "anticipates," "intends," "plans," "predicts," "estimates" and similar expressions.

The forward-looking statements are based on management's current expectations, estimates and projections about us. The Company cautions you that these statements are not guarantees of future performance and involve risks, uncertainties and assumptions that we cannot predict. In addition, the Company has based many of these forward-looking statements on assumptions about future events that may prove to be inaccurate. Accordingly, actual outcomes and results may differ materially from what the Company has expressed or forecast in the forward-looking statements.

You should rely only on the information the Company has provided in this Information Statement. The Company has not authorized any person to provide information other than that provided herein. The Company has not authorized anyone to provide you with different information. You should not assume that the information in this Information Statement is accurate as of any date other than the date on the front of the document.

ADDITIONAL INFORMATION

The Company files reports with the Securities and Exchange Commission (the "SEC"). These reports include annual and quarterly reports, as well as other information the Company is required to file pursuant to securities laws. You may read and copy materials the Company files with the SEC at the SEC's Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at http://www.sec.gov.

BY ORDER OF THE BOARD OF DIRECTORS

/s/ Christopher M. Cashman Name: Christopher M. Cashman Title: President and Chief Executive Officer

April 16, 2012

EXHIBIT INDEX

Exhibit Description

Exhibit A Certificate of Amendment to the Articles of Incorporation

Exhibit A

CERTIFICATE OF AMENDMENT TO THE ARTICLES OF INCORPORATION OF SANUWAVE HEALTH, INC.

The undersigned, pursuant to Section 78.390 of the General Corporation Law of Nevada, certifies, on behalf of SANUWAVE Health, Inc., a Nevada corporation (the "Corporation"), as follows:

1. The Articles of Incorporation of the Corporation are hereby amended in the following fashion:

(A) By deleting the text of the third paragraph thereof referring to the number of shares with par value in its entirety and by adding, in lieu thereof, the following text:

"Number of shares with par value - 155,000,000."

-and-

(B) By adding the following text to the third paragraph thereof:

"The board of directors of the Corporation is hereby vested with the authority to prescribe the classes, series and number of shares of each class or series of stock and the voting powers, designations, preferences, limitations, restrictions and relative rights of each class or series of stock."

2. The Board of Directors of the Corporation adopted resolutions proposing that the amendment be approved by the shareholders of the Corporation, and such amendment was approved by the holders of a majority of the issued and outstanding shares of the Corporation's capital stock entitled to vote on such amendment by written consent executed and delivered to the Corporation in accordance with the provisions of Section 78.320 of the General Corporation Law of Nevada.

3. This Certificate of Amendment has been duly adopted in accordance with the provisions of Section 78.390 of the General Corporation Law of Nevada.

IN WITNESS WHEREOF, the undersigned, a duly authorized representative of the Corporation, has executed this Certificate of Amendment as of _____, 2012.

Christopher M. Cashman, President and CEO

SANUWAVE Health, Inc.

By:

0pt;">

Income (loss) from discontinued operations

18

(7
)
Net income (loss)
\$
37
\$
(438
)
)
\$
ф 78
78
.
\$ (401
(401
)

Earnings (loss) per share:

Basic:

Income (loss) from continuing operations \$ 0.51

\$ (5.93) \$ 0.82

\$ (5.25) Income (loss) from discontinued operations —
0.01
0.25
(0.10)
\$ 0.51
\$ (5.92)
\$ 1.07
\$ (5.35) Diluted:

Income (loss) from continuing operations \$
0.50
\$
(5.93
)
\$
э 0.80
0.00

\$ (5.25) Income (loss) from discontinued operations
0.01
0.24
(0.10)
\$ 0.50
\$ (5.92)
\$ 1.04
\$ (5.35) Weighted average number of common shares outstanding:

Basic 73			
74			
73			

Diluted 74	
74	
75	
75	
Cash dividends declared per share \$ 0.32	
\$ 0.32	
\$ 0.64	
\$ 0.64	
See accompanying combined notes to condensed consolidated financial statements.	

LEIDOS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

	July 3, 2015	nths Ended August 1, 2014	Six Mont July 3, 2015	ths Ended August 1, 2014
	(in millior	/		
Net income (loss)	\$37	\$(438)	\$78	\$(401)
Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustments			(2) —
Deferred taxes			1	
Foreign currency translation adjustments, net of tax			(1) —
Pension liability adjustments			(1) —
Deferred taxes	1		1	
Pension liability adjustments, net of tax	1			
Total other comprehensive income (loss), net of tax	1		(1) —
Comprehensive income (loss)	\$38	\$(438)	\$77	\$(401)

See accompanying combined notes to condensed consolidated financial statements.

LEIDOS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

Cash flows from operations:	Six Months En July 3, 2015 (in millions)	nde	ed August 1, 2014	
Net income (loss)	\$78		\$(401)
(Income) loss from discontinued operations	\$78 (18)	\$(401 7)
Adjustments to reconcile net income to net cash provided by operations:	(10)	/	
Depreciation and amortization	24		34	
	24 14		23	
Stock-based compensation	14			
Goodwill impairment charges			486	
Asset impairment charges	69 (1	``	24	
Other	(1)	5	
Change in assets and liabilities, net of effects of acquisitions and dispositions:	(2)			
Receivables	63		(56)
Inventory, prepaid expenses and other current assets	(10)	9	
Deferred income taxes	23			
Accounts payable and accrued liabilities	14		(35)
Accrued payroll and employee benefits	(20)	12	
Income taxes receivable/payable	(111)	11	
Other long-term assets/liabilities	(16)	(4)
Total cash flows provided by operating activities of continuing operations	109		115	
Cash flows from investing activities:				
Expenditures for property, plant and equipment	(8)	(22)
Payments on accrued purchase price related to prior acquisition	(13)		
Proceeds from sale of assets	5			
Proceeds from U.S. Treasury cash grant			80	
Total cash flows (used in) provided by investing activities of continuing operations	(16)	58	
Cash flows from financing activities:		,		
Payments of notes payable and long-term debt	(47)	(1)
Sales of stock and exercises of stock options	3		4	,
Repurchases of stock and stock received for tax withholdings	(115)	(212)
Dividend payments	(48)	(48	Ś
Other	1	,	1	,
Total cash flows used in financing activities of continuing operations	(206)	(256)
	(,	(,

See accompanying combined notes to condensed consolidated financial statements.

LEIDOS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [CONTINUED] (UNAUDITED)

	Six Months Ended		
	July 3,	August 1,	
	2015	2014	
	(in million	s)	
Decrease in cash and cash equivalents from continuing operations	(113) (83)
Cash flows from discontinued operations:			
Cash provided by operating activities of discontinued operations	13	3	
Cash provided by investing activities of discontinued operations	6	8	
Increase in cash and cash equivalents from discontinued operations	19	11	
Total decrease in cash and cash equivalents	(94) (72)
Cash and cash equivalents at beginning of period	459	430	
Cash and cash equivalents at end of period	\$365	\$358	

See accompanying combined notes to condensed consolidated financial statements.

LEIDOS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	July 3, 2015 (in millions)	January 30, 2015
ASSETS		
Current assets:	* • • • •	*
Cash and cash equivalents	\$365	\$443
Receivables, net	929	896
Inventory, prepaid expenses and other current assets	299	273
Assets held for sale	99	
Assets of discontinued operations	—	6
Total current assets	1,692	1,618
Property, plant and equipment (less accumulated depreciation and amortization of \$315 million and \$313 million at July 3, 2015 and January 30, 2015, respectively)	178	308
Goodwill and intangible assets, net	1,239	1,244
Deferred income taxes	14	14
Other assets	88	97
Note receivable from Leidos Holdings, Inc.	1,561	1,412
	\$4,772	\$4,693
LIABILITIES AND STOCKHOLDER'S EQUITY		
Current liabilities:		
Accounts payable and accrued liabilities	\$716	\$675
Accrued payroll and employee benefits	273	264
Notes payable and long-term debt, current portion	2	2
Liabilities held for sale	2	
Liabilities of discontinued operations	3	10
Total current liabilities	996	951
Notes payable and long-term debt, net of current portion	1,127	1,164
Other long-term liabilities	169	168
Commitments and contingencies (Notes 10 and 11)		
Stockholder's equity:		
Common stock, \$.01 par value, 10,000 shares authorized, 5,000 shares issued and		
outstanding at July 3, 2015 and January 30, 2015	—	_
Additional paid-in capital	207	207
Accumulated earnings	2,284	2,214
Accumulated other comprehensive loss	(11) (11
Total stockholder's equity	2,480	2,410
	\$4,772	\$4,693

See accompanying combined notes to condensed consolidated financial statements.

)

LEIDOS, INC. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

	Three Months Ended		Six Months	Ended	
	July 3,	August 1,	July 3,	August 1,	
	2015	2014	2015	2014	
	(in millions	·			
Revenues	\$1,257	\$1,306	\$2,503	\$2,618	
Costs and expenses:					
Cost of revenues	1,113	1,119	2,206	2,260	
Selling, general and administrative expenses	51	87	126	171	
Goodwill impairment charges		486		486	
Asset impairment charges	29	24	69	24	
Operating income (loss)	64	(410) 102	(323)	
Non-operating income (expense):					
Interest expense, net	(10)	(16) (21)	(34)	
Other income (expense), net	2	(1) 1	1	
Income (loss) from continuing operations before income taxes	56	(427) 82	(356)	
Income tax expense	(17)	(10) (18)	(35)	
Income (loss) from continuing operations	39	(437) 64	(391)	
Discontinued operations:					
Income (loss) from discontinued operations before income taxes		2		(11)	
Income tax (expense) benefit		(1) 18	4	
Income (loss) from discontinued operations		1	18	(7)	
Net income (loss)	\$39	\$(436) \$82	\$(398)	

See accompanying combined notes to condensed consolidated financial statements.

LEIDOS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

	Three Months Ended July 3, August 1,		Six Mont July 3,	hs Ended August 1,
	2015	2014	2015	2014
	(in millior	is)		
Net income (loss)	\$39	\$(436)	\$82	\$(398)
Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustments			(2) —
Deferred taxes			1	
Foreign currency translation adjustments, net of tax			(1) —
Pension liability adjustments			(1) —
Deferred taxes	1		1	
Pension liability adjustments, net of tax	1			
Total other comprehensive income (loss), net of tax	1		(1) —
Comprehensive income (loss)	\$40	\$(436)	\$81	\$(398)

See accompanying combined notes to condensed consolidated financial statements.

LEIDOS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Six Months En July 3, 2015 (in millions)	nded August 1, 2014	
Cash flows from operations:			
Net income (loss)	\$82	\$(398)
(Income) loss from discontinued operations	(18) 7	
Adjustments to reconcile net income to net cash provided by operations:		,	
Depreciation and amortization	24	34	
Stock-based compensation	14	23	
Goodwill impairment charges		486	
Asset impairment charges	69	24	
Other	(5) 2	
Change in assets and liabilities, net of effects of acquisitions and dispositions:	× ×	,	
Receivables	63	(56)
Inventory, prepaid expenses and other current assets	(10) 9	<i>,</i>
Deferred income taxes	23	<i></i>	
Accounts payable and accrued liabilities	14	(35)
Accrued payroll and employee benefits	(20) 12	<i>,</i>
Income taxes receivable/payable	(111) 11	
Other long-term assets/liabilities	(16) (4)
Total cash flows provided by operating activities of continuing operations	109	115	
Cash flows from investing activities:			
Proceeds on obligations of Leidos Holdings, Inc.	17	55	
Payments on obligations of Leidos Holdings, Inc.	(176) (310)
Expenditures for property, plant and equipment	(8) (22)
Payments on accrued purchase price related to prior acquisition	(13) —	<i>,</i>
Proceeds from sale of assets	5	<i></i>	
Proceeds from U.S. Treasury cash grant		80	
Total cash flows used in investing activities of continuing operations	(175) (197)
Cash flows from financing activities:	× ×	<i>,</i> , ,	<i>,</i>
Payments of notes payable and long-term debt	(47) (1)
Total cash flows used in financing activities of continuing operations	(47) (1	ý
Decrease in cash and cash equivalents from continuing operations	(113) (83)
Cash flows from discontinued operations:	× ·	/ (,
Cash provided by operating activities of discontinued operations	13	3	
Cash provided by investing activities of discontinued operations	6	8	
Increase in cash and cash equivalents from discontinued operations	19	11	
Total decrease in cash and cash equivalents	(94) (72)
Cash and cash equivalents at beginning of period	459	430	,
Cash and cash equivalents at end of period	\$365	\$358	

See accompanying combined notes to condensed consolidated financial statements.

Note 1—Summary of Significant Accounting Policies:

Nature of Operations and Basis of Presentation

Leidos Holdings, Inc. ("Leidos") is a holding company whose direct 100%-owned subsidiary is Leidos, Inc., an applied technology company focused on delivering services and solutions that leverage expertise in the national security, health and engineering markets. Leidos, Inc. provides these services and solutions to government and commercial customers, both domestically and internationally. These customers include agencies of the U.S. Department of Defense ("DoD"), the intelligence community, the U.S. Department of Homeland Security ("DHS"), and other U.S. Government civil agencies, state and local government agencies and foreign governments. Unless indicated otherwise, references to the "Company," "we," "us" and "our" refer collectively to Leidos Holdings, Inc., Leidos, Inc., and its consolidated subsidiaries.

The unaudited condensed consolidated financial statements of Leidos and Leidos, Inc. include the accounts of its majority-owned and 100%-owned subsidiaries. Leidos does not have separate operations, assets or liabilities independent of Leidos, Inc., except for a note with Leidos, Inc. (the "related party note"), on which interest is recognized. From time to time, Leidos issues stock to employees of Leidos, Inc. and its subsidiaries, which is reflected in stockholders' equity in Leidos' condensed consolidated balance sheets and results in an increase to the related party note. All intercompany transactions and accounts have been eliminated in consolidation.

The accompanying unaudited condensed financial information has been prepared in accordance with the rules of the U.S. Securities and Exchange Commission ("SEC") and accounting principles generally accepted in the United States of America ("GAAP"). Certain disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis, including those relating to allowances for doubtful accounts, inventories, fair value and impairment of intangible assets and goodwill, income taxes, estimated profitability of long-term contracts, pension benefits, stock-based compensation expense, contingencies and litigation. Estimates have been prepared by management on the basis of the most current and best available information; however, actual results could differ materially from those estimates. Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which consist of normal recurring adjustments, necessary for a fair presentation thereof. The results reported in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for the entire year. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and combined notes thereto included in the Company's Annual Report on Form 10-K.

Fiscal Year End Change

On March 20, 2015, the Board of Directors of the Company approved the amendment and restatement of the bylaws of the Company to change both Leidos' and Leidos, Inc.'s year end from the Friday nearest the end of January to the

Friday nearest the end of December.

As a result of this change, the Company will file its Annual Report on Form 10-K, which will cover the 11 month period ending on January 1, 2016, as its transition report. This change does not impact the Company's prior year, which ended January 30, 2015.

In order to allow an immediate transition to the new calendar and to maintain transparency and comparability of financial information included in the Company's quarterly Form 10-Q filings, the year-to-date information in this Form 10-Q is being presented on a six month basis for the current year which includes the last month of the year

ended January 30, 2015. Therefore, the condensed consolidated statements of income and comprehensive income and the condensed consolidated statements of cash flows reflect the results for the six month period ended July 3, 2015. The Company's business is primarily driven by productive hours and time sold in relation to the services and solutions provided to its customers, as such the productive hours and time sold do not vary materially quarter over quarter. Therefore, the Company does not believe that the change in its year end has a material effect on the comparability of the periods presented. As such, the quarterly periods of the prior year have not been recast to correspond with the new quarterly periods.

The following table shows the periods included in each quarter and year end:

Period	Current year	Prior year
First Quarter	January 3, 2015 to April 3, 2015	February 1, 2014 to May 2, 2014
Second Quarter	April 4, 2015 to July 3, 2015	May 3, 2014 to August 1, 2014
Third Quarter	July 4, 2015 to October 2, 2015	August 2, 2014 to October 31, 2014
Year End	January 31, 2015 to January 1, 2016 (transition period)	February 1, 2014 to January 30, 2015

As a result of the overlap of the month of January 2015 between the fourth quarter of the prior year and the first quarter of the current year, \$373 million of revenue and \$23 million of operating loss from January 2015 is included in the condensed consolidated statements of income and comprehensive income for the six months ended July 3, 2015, which was also included in the Company's results for the year ended January 30, 2015 included in the Company's Form 10-K as filed on March 25, 2015.

In addition, the condensed consolidated statement of cash flows includes previously reported January results which had \$16 million of cash used due to \$11 million of cash provided by operating activities, \$47 million of cash used in financing activities and \$20 million of cash provided by discontinued operations.

Separation Transaction and Restructuring Expenses

During the year ended January 31, 2014, Leidos completed the spin-off of its technical services and enterprise information technology services business. In anticipation of the spin-off, the Company initiated a program to align the Company's cost structure for post-spin-off and incurred severance and lease termination costs.

For the six months ended July 3, 2015, the Company incurred approximately \$2 million of lease termination expenses in its Corporate and Other segment related to an adjustment to reserves established in prior years for loss on leases in connection with revised sublease income assumptions. The Company did not incur any lease termination expenses for the quarter ended July 3, 2015. For the six months ended August 1, 2014, the Company incurred approximately \$1 million of lease termination expenses. The Company incurred no lease termination expenses for the quarter ended August 1, 2014. The separation transaction and restructuring expenses are recorded within "Selling, general and administrative expenses" in the Company's condensed consolidated statements of income. The restructuring liability for lease termination expenses as of July 3, 2015 decreased by \$2 million to \$9 million from January 30, 2015 due to cash payments. The Company does not expect to incur significant additional separation transaction and restructuring expenses in the current year related to the spin-off transaction.

Fair Value Measurements

The accounting standard for fair value measurements establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: observable inputs such as quoted prices in active markets (Level 1);

Edgar Filing: SANUWAVE Health, Inc. - Form DEF 14C

inputs other than the quoted prices in active markets that are observable either directly or indirectly (Level 2); and

unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions (Level 3).

The fair value of financial instruments is determined based on quoted market prices, if available, or management's best estimate. It is management's belief that the carrying amounts of the Company's financial instruments other than derivatives, which include cash equivalents and long-term investments, are reasonable estimates of their related fair values. The carrying value of accounts receivable, accounts payable, and accrued expenses approximate their fair values. The fair value of long-term debt (see Note 5) is determined based on current interest rates available for debt with terms and maturities similar to the Company's existing debt arrangements (Level 2 inputs).

The Company's cash equivalents were primarily comprised of investments in several large institutional money market funds and bank deposits. There are no restrictions on the withdrawal of the Company's cash and cash equivalents. The Company's cash equivalents are recorded at historical cost, which equals fair value based on quoted market prices (Level 1 input).

Management evaluates its investments for other-than-temporary impairment at each balance sheet date. When testing long-term investments for recovery of carrying value, the fair value of long-term investments is determined using various valuation techniques and factors, such as market prices of comparable companies (Level 2 input), discounted cash flow models (Level 3 input) and recent capital transactions of the portfolio companies being valued (Level 3 input). If management determines that an other-than-temporary decline in the fair value of an investment has occurred, an impairment loss is recognized to reduce the investment to its estimated fair value.

The Company's financial instruments measured at fair value on a recurring basis using Level 2 inputs consisted of the Company's interest rate swaps on its \$450 million fixed rate 4.45% notes. At July 3, 2015, the Company did not have any financial assets or liabilities measured at fair value on a recurring basis using Level 3 inputs.

The Company's non-financial instruments measured at fair value on a non-recurring basis included goodwill, indefinite-lived intangible assets and long-lived tangible assets. The valuation methods used to determine fair value require a significant degree of management judgment to determine the key assumptions, as such the Company generally classifies non-financial instruments as either Level 2 or Level 3 fair value measurements. At July 3, 2015, the Company's net assets held for sale related to Plainfield were measured at fair value (Level 1). The Company did not have any non-financial instruments measured at fair value on a non-recurring basis using Level 2 or Level 3 inputs at July 3, 2015.

Changes in Estimates on Contracts

Changes in estimates related to certain types of contracts accounted for using the percentage of completion method of accounting are recognized in the period in which such changes are made for the inception-to-date effect of the changes. Changes in these estimates can routinely occur over the contract performance period for a variety of reasons, including changes in contract scope, contract cost estimates and estimated incentive or award fees. Favorable contract performance resulted in a net increase to operating income of \$5 million and an increase of \$0.04 per diluted share for the quarter ended July 3, 2015, and an increase to operating income of \$10 million and an increase of \$0.08 per diluted share for the six months ended July 3, 2015. Favorable contract performance resulted in a net increase to operating income of \$10 million and an increase to operating income of \$6 million and an increase of \$0.06 per diluted share for the quarter ended August 1, 2014, and an increase to operating income of \$10 million and an increase to an increase to \$0.15 per diluted share for the six months ended August 1, 2014.

Supplementary Cash Flow Information

Supplementary cash flow information, including non-cash investing and financing activities, for the periods presented was as follows:

	Six Months Ended	
	July 3,	August 1,
	2015	2014
	(in million	ns)
Vested stock issued as settlement of annual bonus accruals	\$1	\$1
Stock issued in lieu of cash dividends	\$1	\$2
Accrued dividends declared	\$24	\$—
Cash paid for interest (including discontinued operations)	\$33	\$37
Cash paid for income taxes, net of refunds (including discontinued operations)	\$87	\$12
A second in a Chan de de de de de de de de Net Net Net A de stad		

Accounting Standards Updates Issued But Not Yet Adopted

In May 2014, the Financial Accounting Standards Board ("FASB") issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). This ASU affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets unless those contracts are within the scope of other standards. This ASU will supersede all revenue recognition requirements in Topic 605, Revenue Recognition and industry-specific guidance throughout the Industry Topics of the codification. The guidance's core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In applying the revenue principles, an entity will identify the contract(s) with a customer, identify the performance obligations, determine the transaction price, allocate the transaction price to the performance obligations and recognize revenue when the performance obligation is satisfied (either over time or point in time). The amendments in this ASU are effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2016, for public companies. In July 2015, the FASB approved a one-year deferral of the effective date of the ASU to December 15, 2017, with an option to early adopt the standard on the original effective date. Early adoption prior to the original effective date is not permitted. The Company is still evaluating the provisions of ASU 2014-09 and its impact on the Company's condensed consolidated financial position, results of operations, or cash flows.

Various other accounting standards updates were issued but are not effective for the Company until periods subsequent to July 3, 2015. These updates include guidance to present debt issuance cost as a reduction of the related debt liability as opposed to an asset; the Company is still evaluating the impact of this update. For the other updates issued, which include guidance to eliminate extraordinary items on the statements of income, guidance that changes the evaluation criteria for consolidation, and guidance regarding the timing surrounding the measurement of retirement benefits for entities; the Company does not expect these updates to have a material impact on its condensed consolidated financial position, results of operations, or cash flows.

Note 2—Dispositions:

Dispositions

Plainfield Renewable Energy Holdings LLC

In October 2013, the Company gained control of 100% of the equity interest in Plainfield Renewable Energy Holdings, LLC ("Plainfield") through the consensual foreclosure agreement which constituted a change in control accounted for as a business combination. Plainfield is a 37.5 megawatt biomass-fueled power plant (the "Plant"). In March 2015, the Company entered into a definitive Membership Interest Purchase Agreement ("the Agreement") to sell 100% of the equity membership interest in Plainfield. The Company adjusted the carrying values of Plainfield's assets to their fair values based on the estimated selling price of the business pursuant to the terms of the agreement (Level 1). The carrying value exceeded the fair value which resulted in approximately \$40 million of impairment charges recorded in January 2015 in the Health and Engineering segment.

During the quarter ended July 3, 2015, further negotiations occurred related to the sale of Plainfield resulting in certain closing conditions being waived. As a result, the Company determined that a sale of Plainfield was probable and classified Plainfield as "Held for Sale" in Leidos' condensed consolidated balance sheet as of July 3, 2015. Additionally, as of July 3, 2015, the Company adjusted the carrying values of Plainfield's assets down to the fair value of the anticipated consideration to be received pursuant to an amendment to the Agreement (Level 1), resulting in approximately \$29 million of asset impairment charges. The adjustment related to a reduction in the purchase price, the recapture of previously recognized tax benefits, and incurred transaction costs.

On July 17, 2015, the Company executed an amendment to the Agreement based on prior negotiations and completed the sale on July 24, 2015 of its equity interests in Plainfield for an aggregate consideration of \$101 million, subject to certain adjustments, and contingent earn-out payments. The consideration received by the Company at closing consisted of a cash payment of approximately \$29 million (the "Closing Payment") and a secured promissory note for approximately \$73 million (the "Note"). Payments under the Note are secured by a general security interest in the personal property of Plainfield, a pledge of the membership interests of Plainfield and a first mortgage on the real property that comprises the Plant. In addition to the Closing Payment and the Note, the Company is eligible to receive certain contingent earn-out payments not to exceed \$30 million. The Company will recognize any consideration for the contingent earn-out payments when received.

Discontinued Operations for the Year Ended January 30, 2015

In July 2014, the Company committed to plans to dispose of a business primarily focused on full service emergency management consulting for disaster preparedness, response, recovery, and mitigation historically included in the Company's Health and Engineering segment. The sale transaction was completed in the third quarter ended October 31, 2014 with cash proceeds received of \$19 million, resulting in an immaterial gain on sale.

Discontinued Operations for the Year Ended January 31, 2014

Separation of New SAIC

The Company completed the spin-off of New SAIC on September 27, 2013. New SAIC was a subsidiary of Leidos prior to the separation date. The spin-off was made pursuant to the terms of a Distribution Agreement and several other agreements entered into between the Company and New SAIC on September 25, 2013. These agreements govern the treatment of existing contracts, proposals, and teaming arrangements where New SAIC will jointly perform work after separation on Leidos contracts.

Other Discontinued Operations

Other non-strategic dispositions were historically included in the Company's National Security Solutions segment. In August 2013, the Company committed to plans to dispose of a business primarily focused on technology used to detect if an individual is concealing explosive devices or other hidden weapons. In the first quarter ended May 2, 2014, the Company adjusted the carrying values of the business's assets to their fair value based on the estimated selling price of the business. The carrying value exceeded the fair value which resulted in approximately \$12 million of impairment charges recorded in discontinued operations, of which \$9 million related to fixed assets and inventory and the remainder related to intangible assets. The sale transaction was completed in the second quarter ended August 1, 2014 with insignificant cash proceeds received, resulting in an immaterial loss on sale.

In January 2014, the Company committed to plans to dispose of Cloudshield Technologies, Inc. ("Cloudshield"), previously acquired in fiscal 2011, which is focused on producing a suite of cybersecurity hardware and associated software and services. The sale transaction was completed in February 2015 with cash proceeds received of \$5 million, resulting in an immaterial gain on sale as of July 3, 2015.

The pre-sale operating results through the date of disposal of the Company's discontinued operations discussed above, for the periods presented were as follows:

	Three Mor	nths Ended	Six Month	s Ended
	July 3,	August 1,	July 3,	August 1,
	2015	2014	2015	2014
	(in million	is)		
Revenues	\$6	\$20	\$14	\$46
Costs and expenses:				
Cost of revenues	6	21	12	43
Selling, general and administrative expenses (including impairment		5	4	19
charges of \$9 million for the six months ended August 1, 2014)		5	4	19
Intangible asset impairment charges				3
Operating loss	\$—	\$(6)	\$(2)	\$(19)
Non-operating income	\$—	\$8	\$2	\$8
Income (loss) from discontinued operations before income taxes	\$—	\$2	\$—	\$(11)
Note 2 Coodwill and Interschip Acceta				

Note 3—Goodwill and Intangible Assets:

The Company's National Security Solutions ("NSS") and Health and Engineering ("HES") reportable segments contain goodwill. The balance and changes in the carrying amount of goodwill by segment were as follows:

NSS	HES	Total	
(in million	s)		
\$788	\$905	\$1,693	
—	(486) (486)
\$788	\$419	\$1,207	
—			
\$788	\$419	\$1,207	
	(in million \$788 \$788 	(in millions) \$788 \$905 (486 \$788 \$419 	(in millions) \$788 \$905 \$1,693 (486) (486 \$788 \$419 \$1,207

Goodwill is tested for impairment at the reporting unit level annually, at the beginning of the fourth quarter, and during interim periods whenever events or circumstances indicate that the carrying value may not be recoverable. There were no goodwill impairments during the six months ended July 3, 2015.

During the second quarter ended August 1, 2014, as part of its normal quarterly procedures, the Company considered both qualitative and quantitative factors associated with each of the Company's reporting units and determined that there were indicators that the carrying values of the Health Solutions and Engineering reporting units may not be fully recoverable due to operating performance shortfalls and forecasted declines of revenues and operating income. Based on the unexpected impacts, the Company conducted an interim goodwill impairment test using the two-step quantitative approach.

The Company utilized both the market and income approach as part of the first step of the two-step quantitative goodwill impairment test to determine the estimated fair value of both the Health Solutions and Engineering reporting units (Level 3 fair value measurement).

Based on the first step of the two-step quantitative goodwill impairment test, the Company determined that the fair values of the Health Solutions and Engineering reporting units were below their carrying values. Due to the fact that indicators of impairments existed, the second step of the two-step quantitative goodwill impairment test was performed to determine the implied fair value of goodwill and the impairment amount of the respective reporting units.

As a result of the second step evaluation, the Company recorded goodwill impairment charges in the Health Solutions and Engineering reporting units of \$369 million and \$117 million, respectively, for the quarter ended August 1, 2014, which represents the difference between the carrying value and the implied fair value. There were no other goodwill impairment charges recorded for the remaining reporting units. No goodwill impairments were identified as part of the Company's annual goodwill impairment evaluation performed in the prior year.

Intangible assets consisted of the following:

	July 3, 2015				January 30,				
	Gross carrying value (in millions)			Net carrying value	Gross carrying value	Accumulated amortization		Net carrying value	
Finite-lived intangible assets:									
Customer relationships	\$70	\$(60)	\$10	\$70	\$(57)	\$13	
Software and technology	61	(43)	18	52	(41)	11	
Total finite-lived intangible assets	131	(103)	28	122	(98)	24	
Indefinite-lived intangible assets:									
In-process research and					9			9	
development					2			9	
Trade names	4			4	4			4	
Total indefinite-lived intangible assets	4	_		4	13	_		13	
Total intangible assets	\$135	\$(103)	\$32	\$135	\$(98)	\$37	

The gross carrying value of finite-lived intangible assets increased from January 30, 2015 due to the addition of an in-process research and development intangible asset that reached technological feasibility and began amortizing as a software and technology intangible asset over its useful life of nine years.

Amortization expense related to amortizable intangible assets was \$3 million and \$5 million for the quarter and six months ended July 3, 2015, respectively, and \$5 million and \$10 million for the quarter and six months ended August 1, 2014, respectively.

For the quarter ended August 1, 2014, the Company determined that certain customer relationship intangible assets associated with Vitalize and maxIT were not recoverable due to lower projected revenue and operating income levels from the associated customers. As a result, the Health and Engineering reportable segment recognized an impairment charge of \$24 million for the quarter and six months ended August 1, 2014 to reduce the carrying value of these intangible assets to their estimated fair values. Fair value was estimated using the income approach based on management's forecast of future cash flows to be derived from the assets' use (Level 3 under the accounting standard for fair value measurement).

The estimated annual amortization expense related to finite-lived intangible assets as of July 3, 2015 was as follows: Year Ending

	(in millions)
January 1, 2016 (remainder of year)	\$4
Fiscal 2016	8
Fiscal 2017	6
Fiscal 2018	4
Fiscal 2019	2
Fiscal 2020 and thereafter	4
	\$28

Note 4—Derivative Instruments and Hedging Activities:

The Company uses a risk management policy to assess and manage cash flow and fair value exposure. The policy permits the use of derivative instruments with certain restrictions. The Company uses interest rate swaps to hedge its fixed rate debt against changes in fair value due to variability in interest rates. The Company does not hold derivative instruments for trading or speculative purposes.

In September 2014, the Company entered into interest rate swap agreements to hedge the fair value with respect to all of the \$450 million aggregate principal outstanding on the Company's fixed rate 4.45% notes maturing in December 2020 (the "Notes"). The objective of these instruments is to hedge the Notes against changes in fair value due to the variability in the six-month LIBOR rate (the benchmark interest rate), which effectively converted the debt into floating interest rate debt. Under the terms of the interest rate swap agreements, the Company will receive semi-annual interest payments at the coupon rate of 4.45% and will pay variable interest based on the six-month LIBOR rate. The counterparties to these agreements are financial institutions.

The interest rate swaps were accounted for as a fair value hedge of the Notes and qualified for the shortcut method of hedge accounting which allows for the assumption of no ineffectiveness reported in earnings. The resulting changes in the fair value of the interest rate swaps are fully offset by the changes in the fair value of the underlying debt (the hedged item). The fair value of the interest rate swaps are determined based on observed values for underlying interest rates on the LIBOR yield curve (Level 2).

The fair value of the Notes is stated at an amount that reflects changes in the benchmark interest rate subsequent to the inception of the interest rate swaps through the reporting date. The cash flows associated with the interest rate swaps are classified as operating activities in the condensed consolidated statement of cash flows.

The fair value of the interest rate swaps and their impact on the related fair value of the debt in the condensed consolidated balance sheet is as follows:

		Hedged items				
July 3, 2015	January 30, 2015	Balance sheet line item	July 3, 2015	January 30, 2015		
\$5	\$17	Notes payable and long-term debt, net of current portion	\$5	\$17		
		2015 2015	July 3, 2015January 30, 2015Balance sheet line item\$5\$17Notes payable and long-term	July 3, 2015January 30, 2015Balance sheet line itemJuly 3, 2015\$5\$17Notes payable and long-term\$5		

Note 5—Debt:

Revolving Credit Facility

Leidos has a revolving credit facility, which is fully and unconditionally guaranteed by Leidos, Inc. which had provided for \$750 million in unsecured borrowing capacity at interest rates determined, at Leidos' option, based on either LIBOR plus a margin or a defined base rate. During the third quarter ended October 31, 2014, the Company amended the credit facility to, among other things, change the ratio of consolidated funded debt to EBITDA that the Company is required to maintain. In connection with the amendment to the credit facility, the Company exercised its right under the credit agreement to voluntarily reduce the combined commitments of the lenders from \$750 million to \$500 million. The maturity date of the credit facility is March 2017. As of July 3, 2015 and January 30, 2015, there were no borrowings outstanding under the credit facility.

The credit facility contains certain customary representations and warranties, as well as certain affirmative and negative covenants. The financial covenants contained in the amended credit facility require that, for a period of four trailing fiscal quarters, the Company maintains a ratio of consolidated funded debt, including borrowings under this credit facility, to EBITDA (adjusted for certain items as defined in the credit facility) of not more than 4.0 to 1.0 until no later than January 29, 2016 and 3.75 to 1.0 thereafter, and a ratio of EBITDA (adjusted for certain items as defined in the credit facility) to interest expense of greater than 3.5 to 1.0. The Company was in compliance with these financial covenants as of July 3, 2015. A failure by the Company to meet these financial covenants in the future could eliminate the Company's borrowing capacity under the credit facility.

The available borrowing capacity on the credit facility may vary each quarter based on the trailing four quarters of EBITDA. If the Company's trailing four quarters of EBITDA declines below a certain threshold in relation to outstanding debt, the borrowing capacity available under the credit facility is reduced. The available borrowing capacity based on the results of the Company's trailing four quarters of EBITDA as of July 3, 2015 is \$500 million. Other covenants in the credit facility restrict certain of the Company's activities, including, among other things, its ability to create liens, dispose of certain assets and merge or consolidate with other entities. The credit facility also contains certain customary events of default, including, among others, defaults based on certain bankruptcy and insolvency events, nonpayment, cross-defaults to other debt, breach of specified covenants, Employee Retirement Income Security Act ("ERISA") events, material monetary judgments, change of control events, and the material inaccuracy of the Company's representations and warranties. In addition, the Company's ability to declare and pay future dividends on Leidos stock may be restricted by the provisions of Delaware law and covenants in the revolving credit facility.

Notes Payable and Long-Term Debt

The Company's notes payable and long-term debt consisted of the following:

	Stated interest rate		Effective interest rate		July 3, 2015	January 30, 2015
	(dollars in m	nilli	ons)			
Leidos Holdings, Inc. senior unsecured notes:						
\$450 million notes, which mature in December 2020 ⁽¹⁾	4.45	%	4.53	%	\$454	\$466
\$300 million notes, which mature in December 2040	5.95	%	6.03	%	221	232
Leidos, Inc. senior unsecured notes:						
\$250 million notes, which mature in July 2032	7.13	%	7.43	%	248	248
\$300 million notes, which mature in July 2033	5.50	%	5.86	%	170	182
Capital leases and other notes payable due on various dates through fiscal 2020	0%-3.7%		Various		36	38
Total notes payable and long-term debt					\$1,129	\$1,166
Less current portion					2	2
Total notes payable and long-term debt, net of current portion					\$1,127	\$1,164
Fair value of notes payable and long-term debt					\$1,114	\$1,152

As a result of executing the interest rate swap agreements, the carrying values of \$454 million and \$466 million (1) include fair value adjustments of \$5 million and \$17 million, respectively, attributable to changes in the benchmark interest rate, the six-month LIBOR rate, from the inception of the interest rate swap agreements to July 3, 2015 and

January 30, 2015, respectively.

During the quarter and six months ended July 3, 2015, the Company repurchased in the open market and retired principal amounts of \$7 million and \$22 million, respectively, on its \$300 million 5.95% notes issued by Leidos Holdings, Inc. maturing in December 2040, and \$11 million and \$25 million, respectively, on its \$300 million 5.50% notes issued by Leidos, Inc. maturing in July 2033. For the quarter and six months ended July 3, 2015, the Company recorded an immaterial gain and \$1 million gain, respectively, for the Leidos, Inc. notes and an immaterial gain on extinguishment of debt for the Leidos Holdings, Inc. notes as part of the partial repayment of the respective notes. The net combined gain represents the difference between the repurchase price of \$17 million and \$45 million, for the quarter and six months ended July 3, 2015, respectively, and the net carrying amount of the notes repurchased less the write-off of a portion of the unamortized debt discount and deferred financing costs on a pro-rata basis to the reduction of debt. The repurchases for the six months ended July 3, 2015 included \$11 million and \$13 million in principal repurchased in January 2015 on the Company's \$300 million 5.95% notes and \$300 million 5.50% notes, respectively, at a repurchase price of \$23 million. The Company recorded the gain on extinguishment of debt in "Other income (expense), net" in the Company's condensed consolidated statements of income.

Interest is payable on the Company's senior unsecured notes on a semi-annual basis with principal payments due on maturity. The senior unsecured notes contain customary restrictive covenants, including, among other things, restrictions on the Company's ability to create liens and enter into sale and leaseback transactions under certain

circumstances. The Company was in compliance with all covenants as of July 3, 2015.

Note 6—Related Party Transactions:

Leidos, Inc. has fully and unconditionally guaranteed the obligations of Leidos under its \$450 million 4.45% notes and \$300 million 5.95% notes. These notes have been reflected as debt of Leidos, Inc. in these condensed consolidated financial statements. Leidos, Inc. has fully and unconditionally guaranteed any borrowings under Leidos' amended and restated revolving credit facility maturing in 2017. Leidos has fully and unconditionally guaranteed the obligations of Leidos, Inc. under its \$300 million 5.50% notes and \$250 million 7.13% notes.

Leidos and Leidos, Inc. have a related party note in connection with a loan of cash between the entities, which is adjusted to reflect issuances of stock by Leidos to employees of Leidos, Inc. and its subsidiaries and Leidos, Inc.'s payment of certain obligations on behalf of Leidos. The related party note bears interest based on LIBOR plus a market-based premium. Portions of the related party note may be repaid at any time. The note automatically extends for successive one-year periods unless either Leidos or Leidos, Inc. provides prior notice to the other party. The note receivable also includes the distribution of the assets and liabilities of New SAIC that occurred at the time of the separation in September 2013. As of July 3, 2015, the note receivable from Leidos Holdings, Inc. to Leidos, Inc. was \$1.6 billion.

Note 7—Accumulated Other Comprehensive Loss:

The components of accumulated other comprehensive loss were as follows:

	July 3, 2015 (in millions)	January 30 2015	,
Foreign currency translation adjustments, net of taxes of \$0 million as of July 3, 2015 and January 30, 2015, respectively	\$—	\$1	
Unrecognized net loss on settled derivative instruments associated with outstanding debt, net of taxes of \$3 million as of July 3, 2015 and January 30, 2015, respectively	(4) (5)
Unrecognized net loss on defined benefit plan, net of taxes of \$5 million as of July 3, 2015 and January 30, 2015, respectively	(7) (7)
Total accumulated other comprehensive loss, net of taxes of \$8 million as of July 3, 2015 and January 30, 2015, respectively	\$(11) \$(11)

Reclassifications from other comprehensive income to net income relating to unrecognized net gain (loss) on settled derivative instruments associated with outstanding debt for the quarter and six months ended July 3, 2015 were not material. There were no reclassifications from other comprehensive income to net income relating to foreign currency translation adjustments or unrecognized net gain (loss) on defined benefit plan during the quarter and six months ending July 3, 2015. Reclassifications for unrecognized gain (loss) on settled derivative instruments associated with outstanding debt are recorded in "Other income (expense), net".

Note 8—Earnings Per Share (EPS):

Basic EPS is computed by dividing income less earnings allocable to participating securities by the basic weighted average number of shares outstanding. Diluted EPS is computed similar to basic EPS, except the weighted average number of shares outstanding is increased to include the dilutive effect of outstanding stock options and other stock-based awards. The Company is required to allocate a portion of its earnings to its unvested stock awards containing nonforfeitable rights to dividends or dividend equivalents (participating securities) in calculating EPS using

the two-class method.

The following table provides a reconciliation of the weighted average number of shares outstanding used to compute basic and diluted EPS for the periods presented:

	Three Mo	Six Months Ended			
	July 3,	August 1,	July 3,	August 1,	
	2015	2014	2015	2014	
	(in millio	ns)			
Basic weighted average number of shares outstanding	73	74	73	75	
Dilutive common share equivalents-stock options and other stock a	wards		2		
Diluted weighted average number of shares outstanding	74	74	75	75	

Anti-dilutive stock-based awards are excluded from the weighted average number of shares outstanding used to compute basic and diluted EPS. For the quarter and six months ended July 3, 2015, there were 2 million and 1 million of outstanding stock options and vesting stock awards, respectively, that were antidilutive. For the quarter and six months ended August 1, 2014, there were 4 million and 3 million of outstanding stock options and vesting stock awards, respectively, that were antidilutive.

In May 2015, the Company entered into an Accelerated Share Repurchase ("ASR") agreement with a financial institution to repurchase shares of the Company's outstanding common stock for an aggregate purchase price of \$100 million. During the second quarter ended July 3, 2015, the Company paid \$100 million to the financial institution and received a total delivery of 2.4 million shares of its outstanding shares of common stock. All shares delivered were immediately retired. The final value of the total shares delivered of \$100 million was allocated to additional paid in capital for the second quarter ended July 3, 2015. The total amount of shares delivered by the financial institution were adjusted by the volume weighted average price of the Company's stock over the valuation period specified in the ASR.

In the year ended January 30, 2015, the Company entered into an Accelerated Share Repurchase ("ASR") agreement with a financial institution to repurchase shares of the Company's outstanding common stock for an aggregate purchase price of \$200 million, resulting in a delivery of 4.5 million shares, completed during the first quarter ended May 2, 2014. The final delivery of approximately 0.8 million shares was completed during the second quarter ended August 1, 2014.

In the year ended January 31, 2014, the Company entered into an ASR agreement with a financial institution to repurchase shares of the Company's outstanding common stock for an aggregate purchase price of \$300 million, resulting in an initial delivery of 5.6 million shares of the Company's outstanding shares of common stock. The final delivery of approximately 1.0 million shares was completed during the first quarter ended May 2, 2014. The delivery of Leidos common stock for the ASR purchases reduced the Company's outstanding shares used to

The delivery of Leidos common stock for the ASR purchases reduced the Company's outstanding shares used to determine the weighted average shares outstanding for purposes of calculating basic and diluted EPS for the periods presented.

Note 9—Business Segment Information:

The Company defines its reportable segments based on the way the chief operating decision maker ("CODM"), currently its chief executive officer, manages the operations of the Company for purposes of allocating resources and assessing performance. The Company has the following reportable segments: National Security Solutions, Health and Engineering, and Corporate and Other.

The segment information for the periods presented was as follows:

	Three M	Six Mon	ths Ended	
	July 3,	August 1,	July 3,	August 1,
	2015 2014		2015	2014
	(in millio	ons)		
Revenues:				
National Security Solutions	\$879	\$925	\$1,741	\$1,869
Health and Engineering	379	381	764	753
Corporate and Other	(1) —	(2) (4)
Total revenues	\$1,257	\$1,306	\$2,503	\$2,618
Operating income (loss):				
National Security Solutions	\$74	\$78	\$136	\$155
Health and Engineering	(7) (482) (14) (459)
Corporate and Other	(3) (6) (20) (19)
Total operating income (loss)	\$64	\$(410) \$102	\$(323)

Asset information by segment is not a key measure of performance used by the CODM. Interest income, interest expense, and provision for income taxes, as reported in the condensed consolidated financial statements, are not part of operating income and are primarily recorded at the corporate level. Under U.S. Government Cost Accounting Standards, indirect costs including depreciation expense are collected in numerous indirect cost pools which are then collectively allocated out to the Company's reportable segments based on a representative causal or beneficial relationship of the costs in the pool to the costs in the base.

Note 10—Legal Proceedings:

Timekeeping Contract with City of New York

In March 2012, the Company reached a settlement with the U.S. Attorney's Office for the Southern District of New York and the City of New York ("City") relating to investigations being conducted by the U.S. Attorney's Office and the City with respect to the Company's contract to develop and implement an automated time and attendance and workforce management system ("CityTime") for certain agencies of the City. As part of this settlement, the Company entered into a deferred prosecution agreement ("DPA") with the U.S. Attorney's Office, under which the Company paid approximately \$500 million and the U.S. Attorney's Office deferred prosecution of a single criminal count against the Company, which alleged that the Company, through the conduct of certain managerial employees and others, caused the City to significantly overpay for the CityTime system. Leidos fully satisfied the requirements of the DPA during its three year term and the DPA expired on March 14, 2015. As a result, the U.S. Attorney's Office filed an application with the Court to dispose of the charge that was filed against Leidos as part of the DPA. On March 16, 2015, the Court entered an order disposing of the pending charge.

In August 2012, the Company entered into an administrative agreement with the U.S. Army, on behalf of all agencies of the U.S. Government that confirms the Company's continuing eligibility to enter into and perform contracts with all agencies of the U.S. Government following the CityTime settlement. The Army has determined that the U.S. Government will have adequate assurances under the terms of the administrative agreement that initiation of

Edgar Filing: SANUWAVE Health, Inc. - Form DEF 14C

suspension or debarment is not necessary to protect the U.S. Government's interests following the CityTime settlement. Under the terms of the administrative agreement, the Company has agreed, among other things, to maintain a contractor responsibility program having the specific elements described in the administrative agreement, including retaining a monitor and providing certain reports to the U.S. Army. The administrative

agreement will continue in effect for five years, provided that the Company may request earlier termination after three years.

Data Privacy Litigation

The Company was previously a defendant in a putative class action, In Re: Science Applications International Corporation ("SAIC") Backup Tape Data Theft Litigation, which was a Multidistrict Litigation ("MDL") action in U.S. District Court for the District of Columbia relating to the theft of computer back-up tapes from a vehicle of a company employee. In May 2014, the District Court dismissed all but two plaintiffs from the MDL action. In June 2014, Leidos and its co-defendant, TRICARE, entered into settlement agreements with the remaining two plaintiffs who subsequently dismissed their claims with prejudice.

On September 20, 2014, the Company was named as a defendant in a putative class action, Martin Fernandez, on Behalf Of Himself And All Other Similarly Situated v. Leidos, Inc. in the Eastern District Court of California, related to the same theft of computer backup tapes. The recent complaint includes allegations of violations of the California Confidentiality of Medical Information Act, the California Unfair Competition Law, and other claims. The Company intends to vigorously defend against these claims.

Derivative and Securities Litigation

Between February and April 2012, alleged stockholders filed three putative securities class actions. One case was withdrawn and two cases were consolidated in the U.S. District Court for the Southern District of New York in In re SAIC, Inc. Securities Litigation. The consolidated securities complaint names as defendants the Company, a former chief financial officer, two former chief executive officers, a former group president and the former program manager on the CityTime program, and was filed purportedly on behalf of all purchasers of the Company's common stock from April 11, 2007 through September 1, 2011. The consolidated securities complaint asserted claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 based on allegations that the Company and individual defendants made misleading statements or omissions about the Company's revenues, operating income and internal controls in connection with disclosures relating to the CityTime project. The plaintiffs sought to recover from the Company and the individual defendants an unspecified amount of damages class members allegedly incurred by buying Leidos' stock at an inflated price. On October 1, 2013, the District Court dismissed many claims in the complaint with prejudice and on January 30, 2014, the District Court entered an order dismissing all remaining claims with prejudice and without leave to replead. The plaintiffs moved to vacate the District Court's judgment or obtain relief from the judgment and for leave to file an amended complaint. On September 30, 2014, the District Court denied plantiffs' motions. The plaintiffs filed a notice of appeal on October 30, 2014 to the United States Court of Appeals for the Second Circuit where the appeal remains pending.

Greek Government Contract

Background and Arbitration. In May 2003, the Company entered into a firm-fixed-price contract with the Hellenic Republic of Greece (the Customer) to provide a Command, Control, Communications, Coordination and Integration System (the System) to support the 2004 Athens Summer Olympic Games (the Olympics) and to serve as the security system for the Customer's public order departments following completion of the Olympics.

In November 2008, the Customer accepted the System in writing pursuant to the requirements of the contract. At the time, the Customer determined that the System substantially complied with the terms of the contract and accepted the System with certain alleged minor omissions and deviations. Upon System acceptance, the Company invoiced the

Customer for approximately \$15 million, representing the undisputed portion of the contract balance owed to the Company. The Customer has not paid this final invoice.

In June 2009, the Company initiated arbitration before the International Chamber of Commerce against the Customer seeking damages for breaches of contract by the Customer. In July 2013, the Company received an arbitral award for approximately \$43 million. The Customer has yet to satisfy the arbitral award. The Company is

Edgar Filing: SANUWAVE Health, Inc. - Form DEF 14C

LEIDOS HOLDINGS, INC. LEIDOS, INC. COMBINED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

pursuing an enforcement action in U.S. District Court for the District of Columbia. In September 2013, the Customer filed a petition in a Greek court seeking to nullify the arbitral award and to stay enforcement of the award in Greece. A hearing on the Customer's nullification request was held in Greece in April 2014. The parties agreed to a stay of the Company's enforcement action in U.S. District Court until the Greek court issued a ruling on the Customer's nullification request. In June 2014, the Athens Court of Appeals annulled the arbitral award. The Company appealed the annulment decision to the Supreme Court of Greece in January 2015 to have the arbitral award reinstated. The Company is continuing to pursue enforcement of the award in the U.S. District Court as is still its right under U.S. and international law. The outcomes of the appeal in Greece and the Company's pending enforcement action are uncertain. Financial Status and Contingencies. As a result of the significant uncertainties on this contract, the Company converted to the completed-contract method of accounting and ceased recognizing revenues for the System development portion of this contract in fiscal 2006. No profits or losses were recorded on the Greek contract for the quarter and six months ended July 3, 2015 and for the same periods ending August 1, 2014. As of July 3, 2015, the Company has recorded \$123 million of losses under the Greek contract, reflecting the Company's estimated total cost to complete the System, assuming the Greek contract value was limited to the cash received to date. Based on the complex nature of this contractual situation and the difficulties encountered to date, significant uncertainties exist and the Company is unable to reliably estimate the ultimate outcome. The Company may reverse a portion of the losses from the Greek contract if it receives payments as provided in the arbitral award.

As of July 3, 2015, the Company has \$17 million of receivables relating to value added tax ("VAT") and tax withholds by the Greek government that the Company has paid and believes it is entitled to recover either as a refund from the taxing authorities or as a payment under the Greek contract. The Company has invoiced the Customer for \$28 million for VAT and filed the appropriate tax returns for \$5 million of withholds and the Customer has failed to make payment or refund the monies. If the Customer fails to pay the outstanding VAT amounts or tax withholds the Company is unable to recover the amount as a refund from the taxing authorities, the Company's total losses on the Greek contract could increase.

The Company has met certain advance payment and performance bonding requirements through the issuance of euro-denominated standby letters of credit. As of July 3, 2015, there were \$4 million in standby letters of credit outstanding relating to the support and maintenance of the System. In the arbitration, the Company was awarded but has not received \$21 million representing the amounts drawn by the Customer in fiscal 2011 on certain standby letters of credit as well as damages. The principal subcontractor has provided to the Company euro-denominated standby letters of credit in the amount of \$17 million as of July 3, 2015, of which \$16 million relates to the delivery of the System. The Company may draw on the subcontractor's standby letters of credit under certain circumstances by providing a statement to the responsible bank that the subcontractor has not fulfilled its obligations under the subcontract.

Other

The Company is also involved in various claims and lawsuits arising in the normal conduct of its business, none of which, in the opinion of the Company's management, based upon current information, will likely have a material adverse effect on the Company's condensed consolidated financial position, results of operations, or cash flows.

Note 11—Other Commitments and Contingencies:

VirnetX, Inc.

In fiscal 2007, the Company transferred several patents to VirnetX Inc., a subsidiary of VirnetX Holding Corp. In consideration of this transfer, the Company received certain license rights and the right to receive a percentage of the consideration received in patent infringement or enforcement claims against third parties. In November 2012, a jury found that Apple Corporation infringed two of the patents that the Company previously transferred to VirnetX and awarded approximately \$368 million to VirnetX, but the United States Court of Appeals for the Federal Circuit vacated this award. Although VirnetX petitioned the appeals court for an en banc review, this request was denied and the case has been remanded to the Federal District Court for further proceedings. On December 17, 2014, VirnetX settled a separate patent infringement dispute with Microsoft Corporation, with those parties executing an Amended Settlement and License Agreement. This agreement amended and restated certain terms of the original Settlement and License Agreement, dated May 14, 2010, between VirnetX and Microsoft. Under the terms of the amended agreement, Microsoft agreed to pay \$23 million to VirnetX to settle the patent dispute and expand Microsoft's license. Under its agreements with VirnetX, the Company has recently received from VirnetX proceeds in the amount of \$10 million, \$8 million of which was received after July 3, 2015, from VirnetX's settlement with Microsoft and VirnetX's settlement of a previous litigation matter against various defendants, including Mitel, Siemens, and Avaya. Pursuant to the agreements with VirnetX, the amount received by the Company includes reimbursement for attorneys' fees and costs incurred by the Company in connection with these litigation matters. In addition, the Company is required to pay a royalty on the proceeds received to the customer who paid for the development of the technology. The Company does not have any material assets or liabilities recorded in connection with this matter as of July 3, 2015. Government Investigations and Reviews

The Company is routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect to its role as a contractor to federal, state, and local government customers and in connection with performing services in countries outside of the United States. Adverse findings in these investigations or reviews can lead to criminal, civil or administrative proceedings, and the Company could face penalties, fines, compensatory damages, and suspension or debarment from doing business with governmental agencies. In addition, the Company could suffer serious reputational harm if allegations of impropriety were made against Leidos. Adverse findings could also have a material adverse effect on the Company's business, condensed consolidated financial position, results of operations, and cash flows due to its reliance on government contracts.

U.S. Government agencies, including the Defense Contract Audit Agency ("DCAA"), Defense Contract Management Agency ("DCMA"), and others, routinely audit and review a contractor's performance on government contracts, indirect rates and pricing practices, and compliance with applicable contracting and procurement laws, regulations, and standards. They also review the adequacy of the contractor's compliance with government standards for its business systems, including: a contractor's accounting system, earned value management system, estimating system, materials management and accounting system, property management system, and purchasing system. Both contractors and the U.S. Government agencies conducting these audits and reviews have come under increased scrutiny including such subjects as billing practices, labor charging, and accounting for unallowable costs. As a result, audits and reviews have become more rigorous and the standards to which the Company is held are being more strictly interpreted, increasing the likelihood of an audit or review resulting in an adverse outcome. During the course of its current audits,

the DCAA is closely examining and questioning costs and several of the Company's long established and disclosed practices increasing the uncertainty as to the ultimate conclusion that will be reached. In addition, the Company also monitors compliance with these practices and has an obligation under its contracts to make disclosures of specific improprieties based on credible evidence.

The Company changed its indirect rate structure used in its indirect cost system in fiscal 2011 and future years. The DCAA is performing reviews of these changes and the Company's compliance with certain other U.S. Government Cost Accounting Standards. A finding of significant control deficiencies in the Company's system audits or other reviews can result in cash payments, penalties and potentially decremented billing rates.

The Company's indirect cost audits by the DCAA remain open for fiscal 2009 and subsequent fiscal years. Although the Company has recorded contract revenues subsequent to and including fiscal 2009 based upon an estimate of costs that the Company believes will be approved upon final audit or review, the Company does not know the outcome of any ongoing or future audits or reviews and adjustments, and if future adjustments exceed the Company's estimates, its profitability would be adversely affected.

Pursuant to the Distribution Agreement with New SAIC and upon the separation date, the Company's liability of \$45 million of net amounts to be refunded to customers for potential adjustments from such audit or review of contract costs was allocated to New SAIC in the amount of \$18 million and the Company in the amount of \$27 million. For open periods prior to the spin-off, matters may be settled by the Company with reimbursements due from New SAIC. Subsequent to the separation date, any amounts owed in addition to the \$45 million liability for periods prior to the separation date, any amounts owed in addition to the \$45 million liability for periods prior to the separation date will be apportioned between Leidos and New SAIC in accordance with the Distribution Agreement. As of July 3, 2015, the Company has recorded a total liability of \$44 million for its current best estimate of net amounts to be refunded to customers for potential adjustments from such audits or reviews of contract costs. This amount includes potential adjustments related to both pre-separation and post-separation audits or reviews and excludes amounts assumed to be reimbursed by New SAIC.

Tax Audits and Reviews

The Company files income tax returns in the United States and various state and foreign jurisdictions and is subject to routine compliance reviews by the IRS and other taxing authorities. The Company has effectively settled with the IRS for all fiscal years prior to 2015. With a few exceptions, as of July 3, 2015, the Company is no longer subject to state, local, or foreign examinations by the tax authorities for years before fiscal 2012.

As of July 3, 2015, the balance of unrecognized tax benefits included liabilities for uncertain tax positions of \$19 million, \$5 million of which were classified as other long-term liabilities in the condensed consolidated balance sheet. During the next 12 months, it is reasonably possible that resolution of reviews by taxing authorities, both domestic and international, could be reached with respect to \$13 million of the Company's unrecognized tax benefits, depending on the timing of ongoing examinations, any litigation and expiration of statute of limitations, either because the Company's tax positions are sustained or because the Company agrees to their disallowance and pays the related income tax.

Letters of Credit and Surety Bonds

The Company has outstanding letters of credit of \$67 million as of July 3, 2015, principally related to guarantees on contracts. The Company also has outstanding surety bonds in the amount of \$239 million, principally related to performance and subcontractor payment bonds on the Company's contracts. The outstanding letters of credit and surety bonds have various terms with the majority of the letters of credit and bonds expiring over the next five fiscal years. Certain letters of credit and surety bonds have auto-renewal periods that will extend their expiration dates past the next five fiscal years.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. The following combined discussion and analysis of Leidos Holdings, Inc.'s ("Leidos") and Leidos, Inc.'s financial condition and results of operations and quantitative and qualitative disclosures about market risk should be read in conjunction with our condensed consolidated financial statements and related combined notes. As Leidos is a holding company and consolidates Leidos, Inc. for financial statement purposes, disclosures that relate to activities of Leidos, Inc. also apply to Leidos, unless otherwise noted. Leidos, Inc.'s revenues and operating expenses comprise 100% of Leidos' revenues and operating expenses. In addition, Leidos, Inc. comprises approximately the entire balance of Leidos' assets, liabilities and operating cash flows. Therefore, the following qualitative discussion is applicable to both Leidos and Leidos, Inc., unless otherwise noted.

The following discussion contains forward-looking statements, including statements regarding our intent, belief, or current expectations with respect to, among other things, trends affecting our financial condition or results of operations, backlog, our industry, government budgets and spending, the impact of competition, and the performance and carrying value of our assets. Such statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those in the forward-looking statements as a result of various factors. Some of these factors include, but are not limited to, the risk factors set forth in our Annual Report on Form 10-K, as updated periodically through our subsequent quarterly reports on Form 10-Q. Due to such uncertainties and risks, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update these factors or to publicly announce the results of any changes to our forward-looking statements due to future events or developments.

All amounts in this "Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)" are presented for our continuing operations.

Unless indicated otherwise, references in this report to the "Company," "we," "us," and "our" refer collectively to Leidos, Leidos, Inc., and its consolidated subsidiaries.

On March 20, 2015, our Board of Directors approved the amendment and restatement of our bylaws to change both Leidos' and Leidos, Inc.'s year end from the Friday nearest the end of January to the Friday nearest the end of December. As a result of this change, we will file our Annual Report on Form 10-K, which will cover the 11 month period ending on January 1, 2016, as our transition report. This change does not impact our prior year, which ended January 30, 2015.

In order to allow an immediate transition to the new calendar and to maintain transparency and comparability of financial information included in our quarterly Form 10-Q filings, the year-to-date information in this Form 10-Q is being presented on a six month basis for the current year which includes the last month of the year ended January 30, 2015. The prior year information is being presented on the basis of our prior year fiscal calendar. Therefore, the quarterly information presented in our MD&A is for the three and six months ended July 3, 2015 and the comparable prior year period is for the three and six months ended August 1, 2014. We do not believe that the change in our year end has a material effect on the comparability of the periods presented as our business is primarily driven by productive hours and time sold which is comparable period over period.

Overview

We are an applied technology company delivering services and solutions that leverage expertise in the national security, health and engineering markets. We bring domain-specific capability to each of our markets, including imagery and signals intelligence, advanced sensing phenomenology, intelligence collection methods, life sciences and power grid engineering. In addition to market-specific capabilities, we have three core areas of technical expertise: data analytics, systems engineering and cybersecurity. Customer needs in our markets span these three core areas of expertise, enabling cross-market innovations for our entire customer set. We provide these services and solutions to

government and commercial customers, both domestically and internationally. Leidos' technically advanced solutions have enabled us to build strong ties with our key domestic customers. These customers include

agencies of the U.S. Department of Defense ("DoD"), the intelligence community, the U.S. Department of Homeland Security ("DHS"), other U.S. Government civil agencies, government agencies of U.S. allies abroad, and state and local government agencies. Substantially all of our revenues and tangible long-lived assets are generated by or owned by entities located in the United States. We operate in the following segments: National Security Solutions; Health and Engineering; and Corporate and Other.

For the year ended January 30, 2015, we generated approximately 79% of our total revenues from contracts with the U.S. Government, either as a prime contractor or a subcontractor to other contractors engaged in work for the U.S. Government. Revenues under contracts with the DoD, including subcontracts under which the DoD is the ultimate purchaser, represented approximately 67% of our total revenues for the year ended January 30, 2015. Accordingly, our business performance is affected by the overall level of U.S. Government spending, especially national security, homeland security, and intelligence spending, and the alignment of our service and product offerings and capabilities with current and future budget priorities of the U.S. Government.

Sales Trend. For the quarter ended July 3, 2015, revenues of \$1.3 billion decreased by \$49 million, or 4%, compared to the quarter ended August 1, 2014 primarily attributable to contract activities associated with support of Overseas Contingency Operations ("OCO Contracts") and continued decline in our commercial health business. See "Results of Operations" below for further discussion of our segment results.

In the first six months of 2015, revenues associated with OCO Contracts were 4.0% of total revenue, compared to 8.4% in the prior year. Management expects a continued reduction in revenue for the remainder of the year related to OCO Contracts, partially offset by recent awards in our international business. These awards added approximately \$2.8 billion to our total backlog for the quarter ended July 3, 2015.

Operating Income Trend. For the quarter ended July 3, 2015, our operating income was \$64 million, a \$474 million increase compared to the quarter ended August 1, 2014. For the quarter ended July 3, 2015, our operating income margin was 5.1% compared to an operating loss margin of 31.4% in the prior year's quarter. This increase in operating income and margin was primarily due to \$510 million of asset impairment charges that occurred during the quarter ended August 1, 2014 as well as \$29 million of asset impairment charges that occurred in the current quarter. See "Results of Operations" below for further discussion of our segment results.

From a macroeconomic perspective, our industry is under general competitive pressures due to declining spending from our largest customer and has required and will require a higher level of cost management focus to allow us to remain competitive. We continue to review our cost structure against our anticipated sales and undertake cost management actions and efficiency initiatives where necessary.

Business Environment and Trends

U.S. Government Markets

The following are updates based on events that have occurred in the political and economic environment since the filing of our Annual Report on Form 10-K.

In February 2015, the FY 2016 federal budget cycle started with the Executive Branch delivering its requested budget to Congress. The FY 2016 budget request seeks an increase in defense and non-defense spending, including \$534 billion for the DoD's annual budget and an additional \$51 billion for Overseas Contingency Operations. The requested funding is \$35 billion more than the spending limits within the Budget Control Act (the "BCA"). The Executive Branch and Congress continue to debate defense spending limits, the balance with civil spending and strategies to address the BCA spending caps. The current debate regarding the FY 2016 budget and the balance of spending between National Security and Civil programs could cause further delays in contract awards and continued uncertainty if not resolved by the October 1, 2015 deadline. The amount and nature of these tradeoffs in the final federal budget could adversely impact our operations, future revenues, and growth prospects.

The Temporary Debt Limit Extension Act suspended the statutory limit on the amount of permissible federal debt (the debt ceiling) until March 15, 2015. On March 16, 2015, the Treasury Department began taking "extraordinary measures" to finance the government. If the debt ceiling is not raised, it is anticipated that the debt ceiling will be reached later this year.

Commercial and International Markets

Sales to customers in commercial markets (approximately 17% of total revenues for the year ended January 30, 2015) help to diversify us from reliance upon U.S. Government business. The commercial markets we serve include health and engineering, security products, cybersecurity and logistics services.

Sales to customers in international markets have historically been an insignificant portion of our revenues. Our recent international contract award will further help to diversify us from reliance upon U.S. Government business though will increase our exposure to these markets and the associated international regulatory and geopolitical risks therein. Key Performance Measures

The primary financial performance measures we use to manage our business and monitor results of operations are revenue, operating income, cash flows from operations and diluted EPS. We also believe that bookings and backlog are useful measures for management and investors to evaluate our potential future revenues.

Bookings and Backlog. We received net bookings worth an estimated \$4.0 billion and \$4.9 billion during the three and six months ended July 3, 2015. Net bookings represent the estimated amount of revenue to be earned in the future from funded and unfunded contract awards that were received during the year, net of any adjustments to previously awarded backlog amounts. We calculate net bookings as the year's ending backlog plus the year's revenues less the prior year's ending backlog and less the backlog obtained in acquisitions during the year. Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts as work is performed. Funded backlog for contracts with government agencies primarily represents contracts for which funding is appropriated less revenues previously recognized on these contracts. Negotiated unfunded backlog represents estimated amounts of revenue to be earned in the future from (1) negotiated contracts for which funding has not been appropriated or otherwise authorized and (2) unexercised priced contract options.

The estimated value of our total backlog as of the dates presented was as follows:

The estimated value of our total backlog as of the dates presented was as	Ionows:		
	July 3,	April 3,	January 30,
	2015	2015	2015
	(in million	s)	
National Security Solutions:			
Funded backlog	\$1,859	\$1,786	\$1,596
Negotiated unfunded backlog	6,638	4,073	4,491
Total National Security Solutions backlog	\$8,497	\$5,859	\$6,087
Health and Engineering:			
Funded backlog	\$921	\$975	\$1,061
Negotiated unfunded backlog	806	636	645
Total Health and Engineering backlog	\$1,727	\$1,611	\$1,706
Total:			
Funded backlog	\$2,780	\$2,761	\$2,657
Negotiated unfunded backlog	7,444	4,709	5,136
Total backlog	\$10,224	\$7,470	\$7,793

We expect to recognize a substantial portion of our funded backlog as revenues within the next 12 months. However, the U.S. Government may cancel any contract at any time through a termination for the convenience of the U.S. Government. In addition, certain contracts with commercial customers include provisions that allow the customer to cancel at any time. Most of our contracts have cancellation terms that would permit us to recover all or a portion of our incurred costs and fees for work performed.

30

Results of Operations

The following table summarizes our results of operations for the periods presented:

	Three N	Three Months Ended Si									Six Months Ended						
	July 3,		August	1,	Dollar		Percer	nt	July 3,		August 1,		Dollar		Percer	nt	
	2015		2014		change		change 2		2015		2014		change		chang	e	
	(dollars	s in	millions))													
Revenues	\$1,257		\$1,306		\$(49)	(4)%	\$2,503		\$2,618		\$(115)	(4)%	
Cost of revenues	1,113		1,119		(6)	(1)%	2,206		2,260		(54)	(2)%	
Selling, general and																	
administrative expenses:																	
General and	27		57		(30)	(53)%	77		113		(36)	(32)%	
administrative								, ,						-			
Bid and proposal	17		19		(2)	(11)%	34		38		(4)	(11)%	
Internal research and	7		11		(4)	(36)%	15		20		(5)	(25)%	
development					(-		(,					(-		(,,-	
Goodwill impairment			486		(486)	(100)%			486		(486)	(100)%	
charges							× ·	,					× ·		× ·	/	
Asset impairment	29		24		5		21	%	69		24		45		188	%	
charges	<i>C</i> A		(410	`	4774		116	01	100		(202	``	105		100	Ø	
Operating income (loss)		01	(410)	474		116	%	102	01	(323)	425		132	%	
Operating margin	5.1	%	(31.4)%					4.1	%	(12.3)%					
Non-operating expense,	(12)	(20)	8		40	%	(27)	(38)	11		29	%	
net																	
Income (loss) from	52		(430	`	482		112	01	75		(361	`	436		121	%	
continuing operations before income taxes	32		(430)	462		112	%0	15		(301)	430		121	%0	
	(15	`	(9)	(6)	(67)07-	(15	`	(33)	18		55	%	
Income tax expense Income (loss) from	(15)	(9)	(6)	(07)%	(15)	(33)	10		55	70	
continuing operations	37		(439)	476		108	%	60		(394)	454		115	%	
Income (loss) from																	
discontinued operations,			1		(1)	(100)%	18		(7)	25		NM		
net of tax			1		(1)	(100	10	10		()	,	23		TATAT		
Net income (loss)	\$37		\$(438)	\$475		108	%	\$78		\$(401)	\$479		119	%	
NM - Not meaningful	ΨJI		ψ(τυ)	$\psi \tau i J$		100	10	ΨΙΟ		Ψ(ΤΟΙ	,	ψτιγ		117	70	

NM - Not meaningful

We classify indirect costs incurred within or allocated to our government customers as overhead (included in cost of revenues) and general and administrative expenses in the same manner as such costs are defined in our disclosure statements under U.S. Government Cost Accounting Standards. Effective January 31, 2015, we updated our disclosure statements, resulting in certain costs being classified differently either as cost of revenues or as general and administrative expenses on a prospective basis. These changes did not have an overall impact on the total expense or income reported.

Long-Lived Asset Impairment Evaluations.

Goodwill Interim Impairment Evaluation. In the quarter ended August 1, 2014, our Health Solutions and Engineering reporting units within the Health and Engineering reportable segment were adversely impacted by certain unexpected

events that caused us to reassess current year and future year performance expectations for both reporting units. Based on significant declines in revenue volumes and delayed award decisions, we conducted an interim goodwill impairment test using the two-step quantitative approach.

As a result, we recorded goodwill impairment charges in the Health Solutions and Engineering reporting units of \$369 million and \$117 million, respectively, for the three and six months ended August 1, 2014. See Note 3 within our combined notes to condensed consolidated financial statements for further information.

Property, Plant & Equipment Evaluation. In March 2015, we entered into a definitive Membership Interest Purchase Agreement (the "Agreement") to sell 100% of our equity membership interest in Plainfield. We adjusted the carrying values of Plainfield's assets to their fair values based on the estimated selling price of the business pursuant to the terms of the agreement (Level 1 fair value measurement). The carrying value exceeded the fair value which resulted in approximately \$40 million of asset impairment charges recorded in January 2015.

During the quarter ended July 3, 2015, further negotiations occurred related to the sale of Plainfield resulting in certain closing conditions being waived. As a result, management determined that a sale of Plainfield was probable and we classified Plainfield as "Held for Sale" in Leidos' condensed consolidated balance sheets as of July 3, 2015. Additionally, as of July 3, 2015, we adjusted the carrying values of Plainfield's assets down to the fair value of the anticipated consideration to be received pursuant to an amendment to the Agreement (Level 1), resulting in approximately \$29 million of asset impairment charges. The adjustment related to a reduction in the purchase price, the recapture of previously recognized tax benefits and incurred transaction costs.

Reportable Segment Results. The following table summarizes changes in National Security Solutions revenues and operating income for the periods presented:

	Three Months Ended							Six Months Ended								
National Security Solution	July 3,	August 1,	, Dollar		ar Percent .		July 3,		August 1,		Dollar		Percer	nt		
	2015	2014	change		change		2015		2014		change		change			
	(dollars in	n millions)														
Revenues	\$879	\$925	\$(46)	(5)%	\$1,741		\$1,869		\$(128)	(7)%		
Operating income	74	78	(4)	(5)%	136		155		(19)	(12)%		
Operating income margin	8.4 %	8.4 %					7.8	%	8.3	%						

National Security Solutions revenues decreased \$46 million, or 5%, for the three months ended July 3, 2015 as compared to the three months ended August 1, 2014. Revenue contraction was primarily attributable to contract activities associated with OCO Contracts (\$51 million) which includes a reduction of airborne programs that support intelligence collection (\$35 million). Excluding the revenue declines associated with OCO Contracts, the remaining revenue for the National Securities Solutions segment increased slightly. OCO Contracts contributed approximately \$50 million in revenues for the quarter.

National Security Solutions revenues decreased \$128 million, or 7%, for the six months ended July 3, 2015 as compared to the six months ended August 1, 2014. Revenue contraction was primarily attributable to OCO Contracts (\$119 million) which includes a reduction of airborne programs that support intelligence collection (\$82 million). National Security Solutions operating income decreased \$4 million, or 5%, for the three months ended July 3, 2015 as compared to the three months ended August 1, 2014. This decrease in operating income was primarily attributable to a decrease in revenues, partially offset by reductions in indirect costs along with improved program performance. National Security Solutions operating income decreased \$19 million, or 12%, for the six months ended July 3, 2015 as compared to the six months ended August 1, 2014. The decrease in operating income was primarily attributable to a decrease in revenues (\$11 million), a decrease in net favorable changes in contract estimates (\$8 million), and facility exit costs which were partially offset by decreases in indirect costs.

The following table summarizes changes in Health and Engineering revenues and operating loss for the periods presented:

	Three Months Ended									Six Months Ended									
Health and Engineering	July 3,		August 1,		Dollar		Percent		July 3,		August	1,	Dollar	Percent					
	2015	2014			change		change		2015		2014		change	change					
	(dollars in millions)																		
Revenues	\$379		\$381		\$(2)	(1)%	\$764		\$753		\$11	1	%				
Operating loss	(7)	(482)	475		99	%	(14)	(459)	445	97	%				
Negative operating margin	(1.8)%	(126.5)%					(1.8)%	(61.0)%							

Health and Engineering revenues for the three months ended July 3, 2015 decreased \$2 million or 1%, for the three months ended August 1, 2014. The slight revenue contraction reflects higher sales volume in our engineering business (\$52 million), which was partially offset by decreased demand in our health business (\$33 million) and timing of security product shipments (\$21 million).

Health and Engineering revenues increased \$11 million, or 1%, for the six months ended July 3, 2015 as compared to the six months ended August 1, 2014. The revenue growth reflects higher sales volume in our engineering business (\$101 million), which was partially offset by decreased demand in our health business (\$73 million) and timing of security product shipments (\$17 million).

Health and Engineering operating loss was \$7 million for the three months ended July 3, 2015 as compared to an operating loss of \$482 million for the three months ended August 1, 2014. The change in operating loss was primarily due to a \$486 million goodwill impairment charge and a \$24 million intangible asset impairment charge that occurred during the quarter ended August 1, 2014, partially offset by a \$29 million tangible asset impairment charge that occurred during the quarter ended July 3, 2015 to adjust the carrying values of Plainfield's assets to their fair values. The change in operating loss was also offset by lower volume of high margin security product shipments in the quarter.

Health and Engineering operating loss was \$14 million for the six months ended July 3, 2015 as compared to an operating loss of \$459 million for the six months ended August 1, 2014. The change in operating loss was primarily due to a \$486 million goodwill impairment charge and a \$24 million intangible asset impairment charge that occurred during the six months ended August 1, 2014, partially offset by a \$69 million tangible asset impairment charge that occurred during the six months ended July 3, 2015 to adjust the carrying values of Plainfield's assets to their fair values.

The following table summarizes changes in Corporate and Other operating loss for the periods presented:

Corporate and Other	Three Months Ended July 3, August 1, Dollar 2015 2014 change (dollars in millions)			Dollar change			Six Mont July 3, 2015		hs Ended August 1, 2014		Dollar change		Percent change	
Operating loss	(donars \$(3			\$3	50	%	\$(20)	\$(19)	\$(1)	(5)%
33														

Corporate and Other operating loss for the three and six months ended July 3, 2015 represents corporate costs that are unallowable under U.S. Government Cost Accounting Standards and certain items that are not directly related to the operating performance of the reportable segments.

Non-Operating Expense.

Leidos Holdings, Inc.

Non-operating expense for the three and six months ended July 3, 2015 decreased \$8 million and \$11 million, respectively, as compared to the three and six months ended August 1, 2014 and was primarily due to a reduction in interest expense.

In September 2014, we entered into interest rate swap agreements on our \$450 million fixed rate 4.45% notes maturing in December 2020. The interest rate swap agreements effectively converted a portion of our fixed-rate debt to floating-rate debt tied to the changes in the six-month LIBOR benchmark interest rate. Interest expense decreased \$6 million and \$11 million for the three and six months ended July 3, 2015, respectively, primarily attributable to the repurchase of \$18 million and \$47 million, respectively, of outstanding debt and entering into interest rate swap agreements.

Leidos, Inc.

Interest income on Leidos, Inc.'s note with Leidos increased \$1 million and \$2 million for the three and six months ended July 3, 2015, respectively, compared to the three and six months ended August 1, 2014. This note may fluctuate significantly from year to year based on changes in the underlying note balance and interest rates throughout the fiscal year.

Provision for Income Taxes. For the three months ended July 3, 2015, our income tax expense was \$15 million compared to an income tax expense of \$9 million for the three months ended August 1, 2014. The increase in income tax expense was primarily due to higher earnings in the second quarter of 2015 compared to the corresponding period in 2014 partly offset by a \$3 million reduction in a valuation allowance as a result of the utilization of a capital loss carryforward.

For the six months ended July 3, 2015, our income tax expense was \$15 million as compared to an income tax expense of \$33 million for the six months ended August 1, 2014. The decrease in income tax expense was primarily due to the utilization of capital losses to offset historical capital gains.

For the six months ended July 3, 2015, our discontinued operations reflect a tax benefit of \$18 million due to the LLC conversion of one of our domestic subsidiaries. This conversion resulted in a deemed liquidation for U.S. tax purposes and triggered tax deductions and an income tax benefit.

Liquidity and Capital Resources

Overview of Liquidity

We had \$365 million in cash and cash equivalents at July 3, 2015, which were primarily comprised of cash held in investments in several large institutional money market funds and bank deposits. We anticipate our principal sources of liquidity for the next 12 months and beyond will be our existing cash and cash equivalents and cash flows from operations. We may also borrow up to \$500 million under our revolving credit facility. The available borrowing capacity under the revolving credit facility is \$500 million as of July 3, 2015.

Our revolving credit facility is backed by a number of financial institutions, matures in March 2017 and, by its terms, can be accessed on a same-day basis. We anticipate our principal uses of cash for the next 12 months and beyond will be for operating expenses, capital expenditures, stock repurchases, dividends, debt retirement, and acquisitions of businesses.

In May 2015, we entered into an Accelerated Share Repurchase ("ASR") agreement with a financial institution to repurchase shares of our outstanding common stock for an aggregate purchase price of \$100 million. During the second quarter ended July 3, 2015, we paid \$100 million to the financial institution and received a total delivery of 2.4 million shares of our outstanding shares of common stock. All shares delivered were immediately retired.

We may from time to time seek to retire or purchase our outstanding debt through cash purchases in the open market, privately negotiated transactions or otherwise. Such repurchases, if any, will depend on prevailing market conditions, our liquidity requirements, contractual restrictions, and other factors. During the three and six months ended July 3, 2015, we paid \$17 million and \$45 million, respectively, to repurchase and retire a principal amount of \$18 million and \$47 million, respectively, of outstanding debt. Included in the six months ended July 3, 2015 amount is \$23 million paid in January 2015 to retire a principal amount of \$24 million of outstanding debt.

We anticipate that our operating cash flows, existing cash and cash equivalents, which have no restrictions on withdrawal, and borrowing capacity under our revolving credit facility will be sufficient to meet our anticipated cash requirements for at least the next 12 months.

Summary of Cash Flows

The following table summarizes cash flow information for the periods presented:

	Six Months Ended		
	July 3,	August 1	,
	2015	2014	
	(in million	s)	
Cash provided by operating activities of continuing operations	\$109	\$115	
Cash (used in) provided by investing activities of continuing operations	(16) 58	
Cash used in financing activities of continuing operations	(206) (256)
Cash provided by operating activities of discontinued operations	13	3	
Cash provided by investing activities of discontinued operations	6	8	
Total decrease in cash and cash equivalents	\$(94) \$(72)

Cash Provided by Operating Activities of Continuing Operations. Cash flows provided by operating activities of continuing operations decreased \$6 million for the six months ended July 3, 2015 as compared to the six months ended August 1, 2014 due to a decrease in net income adjusted for non-cash items, partially offset by a net increase in working capital of \$18 million. Working capital was impacted by a source of cash from accounts receivable attributable to the decrease in the days sales outstanding to 67 days for the six months ended July 3, 2015 as compared to 76 days for the six months ended August 1, 2014 due to the acceleration of customer invoices driven by improvements to our billing process. Working capital was partially offset by a use of cash from an increase of income tax payments for the six months ended July 3, 2015.

Cash (Used in) Provided by Investing Activities of Continuing Operations. We used \$16 million in support of investing activities of continuing operations during the six months ended July 3, 2015, primarily due to \$13 million paid for income tax related matters in connection with a prior acquisition and capital expenditures of \$8 million, offset by proceeds from the sale of property, plant and equipment of \$5 million. We had cash flows provided by investing activities of \$58 million during the six months ending August 1, 2014 including \$80 million of proceeds from the U.S. Treasury cash grant in connection with the Plainfield plant, offset by \$22 million to purchase property, plant, and equipment.

Cash Used in Financing Activities of Continuing Operations. We used \$206 million of cash in support of financing activities of continuing operations during the six months ended July 3, 2015, including the repayment and retirement

of debt of \$45 million, the payment of dividends of \$48 million and \$115 million to repurchase shares of our stock primarily related to the May 2015 ASR as well as repurchases related to employee benefit plans. We used \$256 million of cash in support of financing activities of continuing operations during the six months ended August 1, 2014, including the payment of dividends of \$48 million and \$212 million to repurchase shares of our stock primarily from the March 2014 ASR as well as repurchases related to employee benefit plans.

Cash Provided by Operating Activities of Discontinued Operations. Cash flows provided by operating activities of discontinued operations increased \$10 million for the six months ended July 3, 2015 as compared to the six months ended August 1, 2014, due to an increase of net income of \$31 million associated with the tax benefit received during the six months ended July 3, 2015 for the conversion of a subsidiary to a LLC compared to pre-divestiture net losses during prior period, partially offset by a decrease in pre-divestiture operating activity of \$19 million for certain components of our business.

Cash Provided by Investing Activities of Discontinued Operations. Cash flows provided by investing activities of discontinued operations were \$6 million for the six months ended July 3, 2015 due to cash proceeds received primarily for the sale of a component of our business focused on producing a suite of cybersecurity hardware and associated software and services completed in February 2015.

Leidos, Inc.'s Cash Flows. Any differences in cash flows from operating activities of continuing operations for Leidos, Inc. as compared to Leidos are primarily attributable to changes in interest payments (which reduce cash flows from operating activities of Leidos, Inc.) made by Leidos, Inc. on its note with Leidos and changes in excess tax benefits related to stock-based compensation (which reduce cash flows from operating activities for Leidos).

Leidos, Inc. used cash in investing activities of \$175 million during the six months ended July 3, 2015, including repayments on its related party note with Leidos of \$176 million and \$8 million to purchase property, plant, and equipment, primarily offset by proceeds from the related party note with Leidos of \$17 million. Leidos, Inc. used cash in investing activities of \$197 million during the six months ended August 1, 2014, including repayments on its related party note with Leidos of \$310 million and \$22 million to purchase property, plant, and equipment, offset by proceeds from the related party note with Leidos of \$55 million and \$80 million of proceeds from the U.S. Treasury cash grant.

Outstanding Indebtedness

In September 2014, we entered into interest rate swap agreements to hedge the fair value with respect to all of the \$450 million aggregate principal outstanding on our fixed rate 4.45% notes maturing in December 2020 (the "Notes"). The objective of these instruments is to hedge the Notes against changes in fair value due to the variability in the six month LIBOR rate (the benchmark interest rate), which effectively converted a portion of our debt into floating interest rate debt. Under the terms of the interest rate swap agreements, we will receive semi-annual interest payments at the coupon rate of 4.45% and will pay variable interest based on the six-month LIBOR rate. The counterparties to these agreements are financial institutions.

Our outstanding notes payable and long-term debt consisted of the following:

	Stated intere rate (dollars in m		Effective interest rate ons)		July 3, 2015	January 30, 2015
Leidos Holdings, Inc. senior unsecured notes:						
\$450 million notes, which mature in December 2020 ⁽¹⁾	4.45	%	4.53	%	\$454	\$466
\$300 million notes, which mature in December 2040	5.95	%	6.03	%	221	232
Leidos, Inc. senior unsecured notes:						
\$250 million notes, which mature in July 2032	7.13	%	7.43	%	248	248
\$300 million notes, which mature in July 2033	5.50	%	5.86	%	170	182
Capital leases and other notes payable due on various dates through fiscal 2020	0%-3.7%		Various		36	38
Total notes payable and long-term debt					\$1,129	\$1,166
Less current portion					2	2
Total notes payable and long-term debt, net of current portion					\$1,127	\$1,164
Fair value of notes payable and long-term debt					\$1,114	\$1,152

As a result of executing the interest rate swap agreements, the carrying values of \$454 million and \$466 million include fair value adjustments of \$5 million and \$17 million, respectively, attributable to changes in the benchmark (1) interest rate diverses and LUDOD

¹) interest rate, the six-month LIBOR rate, from the inception of the interest rate swap agreements to July 3, 2015 and January 30, 2015, respectively.

During the three and six months ended July 3, 2015, we repurchased in the open market and retired principal amounts of \$7 million and \$22 million, respectively, on our \$300 million 5.95% notes issued by Leidos Holdings, Inc. maturing in December 2040, and \$11 million and \$25 million, respectively, on our \$300 million 5.50% notes issued by Leidos, Inc. maturing in July 2033. For the three and six months ended July 3, 2015, we recorded an immaterial gain and \$1 million gain, respectively, for the Leidos, Inc. notes and an immaterial gain on extinguishment of debt for the Leidos Holdings, Inc. notes as part of the partial repayment of the respective notes. The net combined gain represents the difference between the repurchase price of \$17 million and \$45 million, for the three and six months ended July 3, 2015, respectively, and the net carrying amount of the notes repurchased less the write-off of a portion of the unamortized debt discount and deferred financing costs on a pro-rata basis to the reduction of debt. The repurchases for the six months ended July 3, 2015 included \$11 million and \$13 million in principal repurchased in January 2015 on our \$300 million 5.95% notes and \$300 million 5.50% notes, respectively, at a repurchase price of \$23 million. We recorded the gain on extinguishment of debt in "Other income (expense), net" in our condensed consolidated statements of income.

The notes payable outstanding as of July 3, 2015 contain financial covenants and customary restrictive covenants, including, among other things, restrictions on our ability to create liens and enter into sale and leaseback transactions under certain circumstances. We were in compliance with all covenants as of July 3, 2015.

Credit Facility. We have a revolving credit facility, which is fully and unconditionally guaranteed by Leidos, Inc. which had provided for \$750 million in unsecured borrowing capacity at interest rates determined, at our option, based on either LIBOR plus a margin or a defined base rate. During the three months ended October 31, 2014, we amended

Edgar Filing: SANUWAVE Health, Inc. - Form DEF 14C

the credit facility to, among other things, change the ratio of consolidated funded debt to EBITDA that we are required to maintain. In connection with the amendment to the credit facility, we exercised our right under the credit agreement to voluntarily reduce the combined commitment of the lenders from \$750 million to \$500 million. The maturity date of the facility is March 2017. As of July 3, 2015 and January 30, 2015, there were no borrowings outstanding under the credit facility.

The credit facility contains certain customary representations and warranties, as well as certain affirmative and negative covenants. The financial covenants contained in the amended credit facility require that, for a period of four trailing fiscal quarters, we maintain a ratio of consolidated funded debt, including borrowings under this facility, to EBITDA (adjusted for certain items as defined in the credit facility) of not more than 4.0 to 1.0 no later than January 29, 2016 and 3.75 to 1.0 thereafter and a ratio of EBITDA (adjusted for certain items as defined in the credit facility) to interest expense of greater than 3.5 to 1.0. We were in compliance with these financial covenants as of July 3, 2015. A failure to meet these financial covenants in the future could eliminate our borrowing capacity under the credit facility.

The available borrowing capacity on the credit facility may vary each quarter based on the trailing four quarters of EBITDA. If our trailing four quarters of EBITDA declines below a certain threshold in relation to outstanding debt, the borrowing capacity available under the credit facility is reduced. Our available borrowing capacity based on the results of our trailing four quarters of EBITDA as of July 3, 2015 is \$500 million.

Off-Balance Sheet Arrangements

We have outstanding performance guarantees and cross-indemnity agreements in connection with certain of our unconsolidated joint venture investments. We also have letters of credit outstanding principally related to guarantees on contracts with foreign government customers and surety bonds outstanding principally related to performance and payment bonds. These arrangements have not had, and management does not believe it is likely that they will in the future have, a material effect on our liquidity, capital resources, operations or financial condition. Commitments and Contingencies

We are subject to a number of reviews, investigations, claims, lawsuits and other uncertainties related to our business. For a discussion of these items, see Note 10 - Legal Proceedings and Note 11 - Other Commitments and Contingencies of the combined notes to the condensed consolidated financial statements for the three months ended July 3, 2015 contained within this Quarterly Report on Form 10-Q.

Critical Accounting Policies

There were no material changes to our critical accounting policies, estimates or judgments during the three months ended July 3, 2015 from those discussed in our Annual Report on Form 10- K for the year ended January 30, 2015. Recently Adopted and Issued Accounting Pronouncements

For a discussion of these items, see Note 1 - Summary of Significant Accounting Policies of the combined notes to the condensed consolidated financial statements for the three months ended July 3, 2015 contained within this Quarterly Report on Form 10-Q.

Effects of Inflation

Approximately half of our revenues are derived from cost-reimbursement type contracts, which are generally completed within one year. Bids for long-term FFP and T&M and FP-LOE contracts typically include sufficient provisions for labor and other cost escalations to cover anticipated cost increases over the period of performance. As a result, our revenues and costs have generally both increased commensurate with inflation and net income as a percentage of total revenues has not been significantly affected.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are exposed to certain market rate risks in the normal course of business. Our current market risk exposures are primarily related to interest rates and foreign currency fluctuations. Our risk management policy authorizes, with board of directors' approval, the limited use of derivative instruments to hedge specific interest rate risks. In September 2014, we entered into interest rate swap agreements on our \$450 million fixed rate 4.45% notes maturing in December 2020. The interest rate swap agreements effectively converted a portion of our fixed-rate debt to floating-rate debt tied to the changes in the six-month LIBOR benchmark interest rate. As a result, we may experience fluctuations in interest expense.

For further discussion of our market risk associated with interest rate risk and foreign currency risk as of January 30, 2015, see "Quantitative and Qualitative Disclosures about Market Risk" in Part II of our Annual Report on Form 10-K for the year ended January 30, 2015.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer (our Chief Executive Officer) and principal financial officer (our Executive Vice President and Chief Financial Officer), has evaluated the effectiveness of Leidos' and Leidos, Inc.'s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934) as of July 3, 2015, and our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the U.S. Securities and Exchange Commission. These disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit doed and communicated to our management, including our principal executive officer and our principal executive file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Changes in Internal Control Over Financial Reporting

There have been no changes in Leidos' or Leidos, Inc.'s internal control over financial reporting that occurred in the quarterly period covered by this report that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

We have provided information about legal proceedings in which we are involved in Note 10 - Legal Proceedings of the combined notes to the condensed consolidated financial statements for the three and six months ended July 3, 2015 contained within this Quarterly Report on Form 10-Q.

In addition to the matters disclosed in Note 10, we are routinely subject to investigations and reviews relating to compliance with various laws and regulations. Additional information regarding such investigations and reviews is set forth in Note 11 - Other Commitments and Contingencies—Government Investigations and Reviews of the combined notes to the condensed consolidated financial statements for the three and six months ended July 3, 2015 contained within this Quarterly Report on Form 10-Q.

Item 1A. Risk Factors.

There were no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the year ended January 30, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

(c)Purchases of Equity Securities by the Company

In December 2013, our board of directors authorized a stock repurchase program (2013 Stock Repurchase Program) under which we may repurchase up to 20 million shares of Leidos common stock. This share repurchase authorization replaced the March 2012 share repurchase authorization of 10 million shares. Stock repurchases may be made on the open market or in privately negotiated transactions with third parties including through accelerated share repurchase agreements. Whether repurchases are made and the timing and actual number of shares repurchased depends on a variety of factors including price, corporate capital requirements, other market conditions, and regulatory requirements. The repurchase program may be accelerated, suspended, delayed or discontinued at any time. The following table presents repurchases of Leidos common stock during the quarter ended July 3, 2015:

Period Sha (or	tal Number of ares	(b) Average Price Paid per Share (or Unit)	(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Repurchase Plans or Programs ⁽²⁾	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units)that May Yet Be Purchased Under the Plans or Programs ⁽²⁾
April 4, 2015 - April 30, 2015 19,	,513	\$41.95		8,113,674
May 1, 2015 - May 31, 2015 ⁽³⁾ 1,9	954,005	41.75	1,951,695	6,161,979
June 1, 2015 - June 30, 2015 8,0)37	41.81		6,161,979
July 1, 2015 - July 3, 2015 ⁽³⁾ 444	4,380	41.74	443,807	5,718,172
Total 2,4	125 025	\$41.75	2,395,502	

The total number of shares purchased includes: (i) shares surrendered to satisfy statutory tax withholdings (1) obligations related to vesting of restricted stock awards; and (ii) shares surrendered in payment of the exercise price of non-qualified stock options and/or to satisfy statutory tax withholdings obligations.

(2) We may repurchase up to 20 million shares of Leidos common stock under the 2013 Stock Repurchase Program, which was publicly announced in December 2013.

(3)

In May 2015, we entered into an Accelerated Share Repurchase ("ASR") agreement with a financial institution, whereby we paid an aggregate of \$100 million and received a total delivery of approximately 2.4 million shares of Leidos outstanding shares of common stock during the second quarter ending July 3, 2015. All shares delivered were immediately retired.

None. Item 4. Mir Not applica Item 5. Oth None. Item 6. Exh	er Information.
Exhibit Number	Description of Exhibit
10.1	Employment Offer Letter dated June 9, 2015. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K as filed with the SEC on June 15, 2015.
10.2	Amendment to Membership Interest Purchase Agreement by and among Leidos Engineering, LLC, Greenleaf Power Consolidated, LLC and Plainfield Renewable Energy, LLC dated July 17, 2015. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K as filed with the SEC on July 23, 2015.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	Interactive Data File.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, each registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 5, 2015

Leidos Holdings, Inc.

/s/ James C. Reagan James C. Reagan Executive Vice President and Chief Financial Officer and as a duly authorized officer Date: August 5, 2015

Leidos, Inc.

/s/ James C. Reagan James C. Reagan Executive Vice President and Chief Financial Officer and as a duly authorized officer

Item 6. Ex	hibits.
Exhibit Number 10.1	Description of Exhibit
	Employment Offer Letter dated June 9, 2015. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K as filed with the SEC on June 15, 2015.
10.2	Amendment to Membership Interest Purchase Agreement by and among Leidos Engineering, LLC, Greenleaf Power Consolidated, LLC and Plainfield Renewable Energy, LLC dated July 17, 2015. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K as filed with the SEC on July 23, 2015.
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101	Interactive Data File.